<SEC-DOCUMENT>0001428336-24-000104.txt : 20241112
<SEC-HEADER>0001428336-24-000104.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112160217
ACCESSION NUMBER:		0001428336-24-000104
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20241111
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HEALTHEQUITY, INC.
		CENTRAL INDEX KEY:			0001428336
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36568
		FILM NUMBER:		241447815

	BUSINESS ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020
		BUSINESS PHONE:		801-727-1000

	MAIL ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHEQUITY INC
		DATE OF NAME CHANGE:	20080227
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hqy-20241111.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09a9bdbb-3152-4f48-a046-792b871de3a5,g:43c4cb01-b918-4d87-8edb-365c83be4dc1,d:d4b1341b2f8740e19bc57280f50b7da2-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>hqy-20241111</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001428336</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="hqy-20241111.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001428336</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-11</xbrli:startDate><xbrli:endDate>2024-11-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id4b1341b2f8740e19bc57280f50b7da2_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:144%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:144%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:144%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 11, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">HEALTHEQUITY, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36568</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">52-2383166</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification Number)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">15 West Scenic Pointe Drive</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Draper</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Utah</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">84020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">801</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">727-1000</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:144%">(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:144%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:144%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.035%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">HQY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%"> </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:138%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:138%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5.02&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2024, HealthEquity, Inc. (the &#8220;Company&#8221;) announced that Jon Kessler, President &amp; Chief Executive Officer of the Company and a member of the Board of Directors (the &#8220;Board&#8221;), will retire from his employment with the Company, effective January 6, 2025, and from the Board, effective April 30, 2025. Mr. Kessler will serve as a Special Advisor to the Company through April 30, 2025 (the &#8220;Kessler Transition Date&#8221;). Mr. Kessler&#8217;s retirement is not due to any disagreement with the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also announced that on November 11, 2024, the Board approved the appointment of Scott R. Cutler as President and Chief Executive Officer, effective as of January 6, 2025 (the &#8220;Commencement Date&#8221;). On November 11, 2024, the Board also expanded the size of the Board to eleven directors and appointed Mr. Cutler to fill the vacancy created by the increased size of the Board, each effective as of the Commencement Date. Mr. Cutler will not serve on any Board committees. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Cutler, age 55, was most recently the Chief Executive Officer of StockX LLC since June 2019. Prior to that, Mr. Cutler was the Senior Vice President, Americas at eBay Inc. from August 2017 to March 2019, President of StubHub, Inc. from April 2015 to August 2017, and an Executive Vice President of NYSE Euronext, Inc. from April 2006 to March 2015. Prior to joining NYSE Euronext, Mr. Cutler was a technology investment banker and corporate securities lawyer. Mr. Cutler serves on the board of directors of Brookfield Renewable Partners L.P. (NYSE: BEP). Mr. Cutler holds a B.S. in economics from Brigham Young University, and a J.D. from the University of California, Hastings College of the Law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cutler Employment Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a written employment agreement dated November 11, 2024 with Mr. Cutler, which was approved by the Board. Mr. Cutler&#8217;s employment agreement provides for &#8220;at-will&#8221; employment and does not have a stated duration or term. Under the terms of the employment agreement, Mr. Cutler is entitled to a base salary of not less than $775,000, is eligible for an annual incentive bonus award with a target of 100% of Mr. Cutler&#8217;s base salary based upon the achievement of corporate and individual performance objectives as determined by the Company&#8217;s talent, compensation and culture committee, including participation in the corporation&#8217;s Executive Bonus Plan for the fiscal year ending January 31, 2025 on a pro rata basis, is entitled to a sign-on bonus in an amount equal to $650,000, which bonus is repayable if Mr. Cutler's employment is terminated for cause or if Mr. Cutler voluntarily resigns without good reason (each, as defined in Mr. Cutler&#8217;s employment agreement, within 12 months of his commencement of employment), and is entitled to an award of restricted stock units (&#8220;RSUs&#8221;) with a fair market value of $7,500,000 (the &#8220;Initial Equity Award&#8221;), with one-third of the RSUs vesting on each of the first three anniversaries of the Commencement Date. In the event Mr. Cutler&#8217;s employment is terminated by the Company without cause (and not within 12 months of a change in control (as defined in Mr. Cutler&#8217;s employment agreement)), Mr. Cutler will vest in a number of RSUs subject to the Initial Equity Award that would have vested during the 12-month period following such termination had Mr. Cutler&#8217;s employment not been terminated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Cutler&#8217;s employment agreement also provides him with the opportunity to receive certain post-employment payments and benefits in the event of certain types of termination of his employment. Upon termination of Mr. Cutler's employment by the Company without &#8220;cause&#8221; or by Mr. Cutler for &#8220;good reason&#8221;, in addition to any compensation that has been accrued or earned but not yet paid, subject to the execution of a general release of claims in favor of the Company and its affiliates, Mr. Cutler would be entitled to: (i) continued payment of his then current annual base salary for 12 months following the termination date (or, in the event such termination occurs during the 12-month period beginning on a change in control of the Company, 18 months following the termination date); (ii) subject to the achievement of the applicable performance conditions for the relevant fiscal year, his annual bonus for the fiscal year in which the termination date occurs, pro-rated based on the number of days which elapsed in the applicable fiscal year through the date of termination, payable at such time annual bonuses are paid to our other executive officers; (iii) an extension of the time to exercise all stock options held as of the date of termination until the earlier of (x) the expiration date of such stock option and (y) the 12-month anniversary of the date of termination; and (iv) subject to Mr. Cutler&#8217;s election of COBRA continuation coverage, provided he does not become eligible to receive comparable health benefits through a new employer, a monthly cash payment equal to the monthly COBRA premium cost for the 12-month period following the date of termination (or, in the event such termination occurs during the 12-month period beginning on a change in control of the Company, the 18-month period following the termination date).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon a termination of Mr. Cutler&#8217;s employment due to death or &#8220;disability&#8221; (as defined in Mr. Cutler&#8217;s employment agreement), in addition to any accrued or earned but unpaid amounts, Mr. Cutler (or Mr. Cutler&#8217;s estate or beneficiaries, as the case may be) would be entitled to, subject to the achievement of the applicable performance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions for the relevant fiscal year, his annual bonus for the fiscal year in which the termination date occurs, pro-rated based on the number of days which elapsed in the applicable fiscal year through the date of termination, payable at such time annual bonuses are paid to our other executive officers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Cutler also signed a Confidentiality, Non-Interference, and Invention Assignment Agreement with the Company which subjects him to customary confidentiality restrictions that apply during his employment and indefinitely thereafter, a covenant not to compete during his employment and for a period of 12 months thereafter, and a non-interference covenant while employed with us and for a period of 24 months thereafter. Generally, the non-compete provisions prevent Mr. Cutler from engaging in consumer healthcare related businesses, including the business of acting as custodian or administrator for medical payment reimbursement accounts and other consumer-directed benefits, including, but not limited to, health savings accounts, flexible spending accounts and health reimbursement accounts, COBRA administration, commuter and other benefits or any other business activities in which we or any of our affiliates are engaged (or have committed plans to engage) during his employment. The non-interference covenant prevents Mr. Cutler from soliciting or hiring our employees or those of our affiliates and from soliciting or inducing any of our customers, suppliers, licensees, or other business relations or those of our affiliates, to cease doing business with us, or reduce the amount of business conducted with us or our affiliates, or in any manner interfering with our relationships with such parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of Mr. Cutler&#8217;s employment agreement is qualified in its entirety by reference to the full text of the employment agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated by reference in this Item 5.02.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into an indemnification agreement with Mr. Cutler. For more information, see the full text of the indemnification agreement, a copy of which is attached hereto as Exhibit 10.2 and incorporated by reference in this Item 5.02.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships between Mr. Cutler and any of the Company&#8217;s directors or executive officers, and, except as described above, there is no arrangement or understanding between Mr. Cutler or any other person and the Company or any of its subsidiaries pursuant to which he was appointed as an officer and director of the Company. There are no transactions between Mr. Cutler or any of his immediate family members and the Company or any of its subsidiaries that would be required to be reported under Item 404(a) of Regulation S-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kessler Transition Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2024, the Company and Mr. Kessler entered into a letter agreement memorializing the terms of his transition (the &#8220;Transition Agreement&#8221;), which provides that while Mr. Kessler serves as a Special Advisor there will be no change to his base salary of $750,000, and Mr. Kessler will remain eligible to earn an annual bonus. While employed with the Company as Special Advisor, Mr. Kessler will report to the Board and is expected to dedicate all of his business time to the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For so long as Mr. Kessler is continuously providing services to the Company in any capacity, each of the options and performance based restricted stock unit (&#8220;PRSUs&#8221;) awards granted to him pursuant to the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Equity Plan&#8221;) and the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Equity Plan&#8221; and, together with the 2014 Equity Plan, the &#8220;Equity Plans&#8221;)) will remain outstanding in accordance with their terms, including, for purposes of any unvested PRSUs, eligible to vest and/or settle based on actual achievement of the applicable performance metrics.  Except as provided below, on the date that Mr. Kessler is no longer providing services to the Company in any capacity, (A) any outstanding PRSUs that have not settled as of such date will be forfeited and (B) Mr. Kessler&#8217;s vested options will remain exercisable for the period set forth in the applicable stock option agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to Mr. Kessler&#8217;s continued employment with the Company through the Kessler Transition Date, upon any termination of his employment as Special Advisor following such time (other than by the Company for cause (as defined in Mr. Kessler&#8217;s employment agreement)), subject to his execution of a release of claims, the Company will provide Mr. Kessler the following benefits: (i) subject to sections 9(c) and 9(d) of the 2024 Equity Plan, Mr. Kessler&#8217;s termination will constitute a &#8220;qualifying retirement&#8221; and the outstanding PRSUs granted to Mr. Kessler in 2024 pursuant to the 2024 Equity Plan will remain outstanding and eligible to satisfy the applicable performance based vesting conditions as though Mr. Kessler had remained in continuous service with the Company through the certification date for such PRSUs; and (ii) subject to the achievement of the applicable performance conditions for the applicable fiscal year, (x) if Mr. Kessler&#8217;s employment terminates after the Kessler Transition Date and prior to January 31, 2025, any bonus for the fiscal year ending January 31, 2025 will be pro-rated based on the number of days in such fiscal year that Mr. Kessler was employed and such amount (if any) will be paid at the same time it would otherwise be paid to Mr. Kessler had no termination occurred, but in no event later than April 15, 2025 and (y) if Mr. Kessler remains employed after January 31, 2025, any bonus for the fiscal year ending January 31, 2026 will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be pro-rated based on the number of days in such fiscal year that Mr. Kessler serves as a Special Advisor and such amount (if any) will be paid at the same time it would otherwise be paid to Mr. Kessler had no termination occurred, but in no event later than April 15, 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the foregoing severance benefits, Mr. Kessler&#8217;s existing post-termination non-competition and non-solicitation obligations have been extended to the third anniversary of the termination of his employment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the letter agreement with Mr. Kessler is qualified in its entirety by reference to the full text of the letter agreement, a copy of which is attached hereto as Exhibit 10.2 and incorporated by reference in this Item 5.02.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A press release dated November 12, 2024 announcing Mr. Kessler&#8217;s retirement and Mr. Cutler&#8217;s appointment as Chief Executive Officer is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.  The information in Item 7.01 of this current report, including Exhibit 99.1 attached hereto, is furnished and shall not be treated as filed for purposes of the Securities Exchange Act of 1934. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="cutler-hqyceoemploymentagr.htm">Employment Agreement, dated November 11, 2024, between Scott R. Cutler and the Company</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="cutler-hqyindemnificationa.htm">Indemnification Agreement, dated November 11, 2024, between Scott R. Cutler and the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="esp-tsavf.htm">Letter Agreement, dated November 11, 2024, between Jon Kessler and the Company</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="goldengateprvf.htm">Press Release, dated November 12, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted in Inline XBRL)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">* Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. HealthEquity hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"/><td style="width:49.782%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HEALTHEQUITY, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Lucania</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Lucania</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cutler-hqyceoemploymentagr.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id53062a59f9b4124964bc1e63c8d5a7d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This EMPLOYMENT AGREEMENT (this&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of this 11th day of November 2024, by and between HealthEquity, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Scott R. Cutler (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">W I T N E S S E T H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to employ Executive and to enter into this Agreement to embody the terms of such employment, and Executive desires to enter into this Agreement and to accept the terms and provisions of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are mutually acknowledged, the Company and Executive hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Definitions.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i)&#160;all accrued but unpaid Base Salary through the date of termination of Executive&#8217;s employment, (ii)&#160;any unpaid or unreimbursed expenses incurred in accordance with Section 7 hereof, and (iii)&#160;any benefits provided under the Company&#8217;s employee benefit plans upon a termination of employment (excluding any employee benefit plan providing severance or similar benefits), in accordance with the terms contained therein.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble hereto.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4(b) hereof.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the salary provided for in Section 4(a) hereof or any increased salary granted to Executive pursuant to Section 4(a) hereof.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i)&#160;Executive&#8217;s act(s) of gross negligence or willful misconduct in the course of Executive&#8217;s employment hereunder&#59; (ii)&#160;willful failure or refusal by Executive to perform in any material respect Executive&#8217;s duties or responsibilities other than by reason of Disability&#59; (iii)&#160;misappropriation (or attempted misappropriation) by Executive of any assets or business opportunities of the Company or any other member of the Company Group&#59; (iv)&#160;embezzlement or fraud committed (or attempted) by Executive, at Executive&#8217;s direction, or with Executive&#8217;s prior actual knowledge&#59; (v)&#160;Executive&#8217;s conviction of or pleading &#8220;guilty&#8221; or &#8220; no contest&#8221; to, (x)&#160;a felony or (y)&#160;any other criminal charge that has, or could be reasonably expected to have, an adverse impact on the performance of Executive&#8217;s duties to the Company or any other member of the Company Group or otherwise result in material injury to the reputation or business of the Company or any other member of the Company Group&#59; (vi)&#160;any material violation by Executive of the written policies of the Company, including but not limited to those relating to sexual harassment, insider trading, or business conduct, and those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">otherwise set forth in the manuals or written statements of policy of the Company&#59; or (vii)&#160;Executive&#8217;s material breach of this Agreement or material breach of the Non-Interference Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If, within ninety (90) days subsequent to Executive&#8217;s termination for any reason other than by the Company for Cause, the Company determines in good faith that Executive&#8217;s employment could have been terminated for Cause pursuant to subparts (iii), (iv), or (v) of the preceding paragraph (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Post-Termination Cause Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Executive&#8217;s employment will be deemed to have been terminated for Cause for all purposes, and Executive will be required to disgorge to the Company all amounts received pursuant to this Agreement or otherwise on account of such termination that would not have been paid or payable to Executive had such termination been by the Company for Cause.  Notwithstanding the foregoing, the Company may assert a Post-Termination Cause Determination if, and only if, the Board did not have actual knowledge of facts supporting its Post-Termination Cause Determination prior to the termination of Executive&#8217;s employment. </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Company&#8217;s 2024 Equity Incentive Plan, as may be in effect from time to time (or any successor equity-based plan as may be in effect from time to time).</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CIC Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period beginning as of the consummation of a Change in Control and ending on the twelve-month anniversary of such Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Part 6 of Title I of the Employee Retirement Income Security Act of 1974, as amended, and Section&#160;4980B of the Code, and the rules and regulations promulgated under any of them.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 2 hereof. </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble hereto.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Company together with any direct or indirect subsidiaries of the Company.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Board or the committee of the Board designated to make compensation decisions relating to senior executive officers of the Company Group.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 13 hereof.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any physical or mental disability or infirmity of Executive that prevents the performance of Executive&#8217;s duties for a period of (i)&#160;ninety (90) consecutive days or (ii)&#160;one hundred twenty (120) non-consecutive days during any twelve (12) month period.  Any question as to the existence, extent, or potentiality of Executive&#8217;s Disability upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which Executive and the Company cannot agree shall be determined by a qualified, independent physician selected and paid for by the Company and approved by Executive (which approval shall not be unreasonably withheld).  The determination of any such physician shall be final and conclusive for all purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the preamble hereto.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, without Executive&#8217;s consent, (i)&#160;a material diminution in Executive&#8217;s title, duties, or responsibilities as set forth in Section 3 hereof such that Executive is no longer serving as President and Chief Executive Officer of the Company and its parent (if any) or if Executive is not recommended for appointment or election to the Board, (ii)&#160;a material reduction in Base Salary set forth in Section 4(a) hereof or Annual Bonus opportunity set forth in Section 4(b) hereof (other than pursuant to an across-the-board reduction applicable to all similarly situated executives as set forth in Section 4(a) hereof), (iii)&#160;the relocation of Executive&#8217;s principal place of employment (as provided in Section 3(c) hereof) more than fifty (50) miles from its current location, or (iv)&#160;any other material breach of a provision of this Agreement by the Company (other than a provision that is covered by clause (i), (ii), or (iii) above).  Executive acknowledges and agrees that Executive&#8217;s exclusive remedy in the event of any breach of this Agreement shall be to assert Good Reason pursuant to the terms and conditions of Section 8(e) hereof. Notwithstanding the foregoing, during the Term, in the event that the Board reasonably believes that Executive may have engaged in conduct that could constitute Cause hereunder, the Board may, in its sole and absolute discretion, suspend Executive from performing Executive&#8217;s duties hereunder, and in no event shall any such suspension constitute an event pursuant to which Executive may terminate employment with Good Reason or otherwise constitute a breach hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no such suspension shall alter the Company&#8217;s obligations under this Agreement during such period of suspension.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Interference Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Confidentiality and Invention Assignment Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, trust (charitable or non-charitable), unincorporated organization, or other form of business entity.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Release of Claims in substantially the same form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as the same may be revised from time to time to comply with law by the Company upon the advice of counsel).</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 8(g) hereof.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 8(d)(iv)</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) the twelve-month period following Executive&#8217;s termination by the Company without Cause (other than by reason of death or Disability) or by Executive for Good Reason, in each case, not occurring during the CIC Period and (ii)&#160;the eighteen-month period following Executive&#8217;s termination by the Company without Cause (other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">than by reason of death or Disability) or by Executive for Good Reason, in each case, occurring during the CIC Period.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the period specified in Section 2 hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Acceptance and Term.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company agrees to employ Executive, and Executive agrees to serve the Company, on the terms and conditions set forth herein.  The Term shall commence on January&#160;6, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and shall continue until terminated in accordance with the provisions of Section 8 hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Position, Duties, and Responsibilities&#59; Place of Performance.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Position, Duties, and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Executive shall be employed and serve as the President and Chief Executive Officer (together with such other position or positions consistent with Executive&#8217;s title as the Board shall specify from time to time) and shall have such duties and responsibilities commensurate with such title.  Executive also agrees to serve as an officer and&#47;or director of any other member of the Company Group, in each case without additional compensation.  Executive shall report to the Board. During the Term, the Executive shall be recommended for appointment and&#47;or election to the Board.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall devote Executive&#8217;s full business time, attention, skill, and best efforts to the performance of Executive&#8217;s duties under this Agreement and shall not engage in any other business or occupation during the Term, including, without limitation, any activity that (x)&#160;conflicts with the interests of the Company or any other member of the Company Group, (y)&#160;interferes with the proper and efficient performance of Executive&#8217;s duties for the Company, or (z)&#160;interferes with Executive&#8217;s exercise of judgment in the Company&#8217;s best interests.  Notwithstanding the foregoing, nothing herein shall preclude Executive from (i)&#160;serving, with the prior written consent of the Board, as a member of the boards of directors or advisory boards (or their equivalents in the case of a non-corporate entity) of non-competing businesses and charitable organizations, (ii)&#160;engaging in charitable activities and community affairs, and (iii)&#160;managing Executive&#8217;s personal investments and affairs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the activities set out in clauses (i), (ii), and (iii) shall be limited by Executive so as not to materially interfere, individually or in the aggregate, with the performance of Executive&#8217;s duties and responsibilities hereunder or create a potential business or fiduciary conflict.  The Board consents to Executive&#8217;s service as a member of the board of directors of Brookfield Renewable Partners (NYSE&#58; BEP) and the non-profit Vibrant Emotional Health.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Principal Place of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive&#8217;s principal place of employment shall be Executive&#8217;s residence in Utah, although Executive understands and agrees that Executive will be required to travel to the Company&#8217;s Draper, Utah headquarters and to other sites and locations as needed for business reasons.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Compensation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the Term, Executive shall be entitled to the following compensation&#58;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall be paid an annualized Base Salary, payable in accordance with the regular payroll practices of the Company, of not less than $775,000, with increases, if any, as may be approved in writing by the Compensation Committee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the foregoing shall not preclude the Company from reducing Executive&#8217;s Base Salary as part of an across-the-board reduction applicable to all similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall be eligible for an annual incentive bonus award determined by the Compensation Committee in respect of each fiscal year during the Term (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The target Annual Bonus for each fiscal year shall be 100% of Base Salary, which Executive will be eligible to earn pursuant to written annual bonus plans delivered to Executive from time to time.  Executive&#8217;s Annual Bonus for fiscal year 2025 shall be prorated based on the number of days worked in that fiscal year.  The Annual Bonus shall be paid to Executive at the same time as annual bonuses are generally payable to other senior executives of the Company, subject to Executive&#8217;s continuous employment through the payment date except as otherwise provided for in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Sign-On Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall receive a one-time sign-on bonus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sign-On Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in an amount equal to $650,000.  The Sign-On Bonus shall be paid to Executive in a single lump sum in cash on the first regularly scheduled payroll date following the Commencement Date.  In the event that Executive&#8217;s employment is terminated by the Company with Cause or by Executive without Good Reason, in each case prior to the first anniversary of the Commencement Date, Executive shall be obligated to promptly (and in any event within five (5) days after such termination) repay 100% of the gross amount of the Sign-On Bonus to the Company.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Initial Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall receive an initial equity award with a grant date fair market value of $7,500,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Initial Equity Award will be granted on or before the Commencement Date.  The Initial Equity Award will consist of time-based restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), one-third (1&#47;3) of which RSUs will vest on each of the first three anniversaries of the Commencement Date&#59; provided, however, that in the event that Executive&#8217;s employment is terminated by the Company without Cause (other than due to death or Disability) not during the CIC Period, Executive will vest in a number of RSUs subject to the Initial Equity Award that would have vested during the twelve-month period following such termination had Executive&#8217;s employment not terminated, subject to Executive&#8217;s execution and non-revocation of the Release of Claims attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to this Agreement.  The Initial Equity Award will be subject to the terms of the Company&#8217;s 2024 Equity Incentive Plan and award agreement evidencing such grant in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Annual Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall be eligible for an annual equity award (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as ultimately and exclusively determined by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Committee in respect of each fiscal year beginning with the fiscal year ending January&#160;31, 2026.  Any Annual Equity Award will be granted in connection with the Company&#8217;s regular grant cycle and on such terms and conditions as may be determined exclusively by the Compensation Committee, and the terms of such grants shall be governed by the terms of the Company&#8217;s 2024 Equity Incentive Plan (or any successor equity-based plan), as well as separate award agreements in the standard forms utilized by the Company for similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Employee Benefits.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the Term, Executive shall be entitled to participate in health, insurance, retirement, and other benefits provided generally to similarly situated executives of the Company.  Executive shall also be entitled to the same number of holidays, vacation days, and sick days, as well as any other benefits, in each case as are generally allowed to similarly situated executives of the Company in accordance with the Company policy as in effect from time to time.  Nothing contained herein shall be construed to limit the Company&#8217;s ability to amend, suspend, or terminate any employee benefit plan or policy at any time without providing Executive notice, and the right to do so is expressly reserved.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Key-Man Insurance.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At any time during the Term, the Company shall have the right to insure the life of Executive for the sole benefit of the Company, in such amounts, and with such terms, as it may determine.  All premiums payable thereon shall be the obligation of the Company.  Executive shall have no interest in any such policy, but agrees to cooperate with the Company in procuring such insurance by submitting to physical examinations, supplying all information required by the insurance company, and executing all necessary documents, provided that no financial obligation is imposed on Executive by any such documents.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Reimbursement of Business Expenses.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the Term, the Company shall pay (or promptly reimburse Executive) for documented, out-of-pocket expenses reasonably incurred by Executive in the course of performing Executive&#8217;s duties and responsibilities hereunder, which are consistent with the Company&#8217;s policies in effect from time to time with respect to business expenses, subject to the Company&#8217;s requirements with respect to reporting of such expenses. In addition, the Company shall promptly reimburse Executive for his reasonable, documented legal fees incurred in connection with the review and negotiation of this Agreement&#59; provided, however, such expense reimbursement shall not exceed $25,000.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Termination of Employment.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Term shall terminate upon the earliest to occur of (i)&#160;Executive&#8217;s death, (ii)&#160;a termination by reason of a Disability, (iii)&#160;a termination by the Company with or without Cause, and (iv)&#160;a termination by Executive with or without Good Reason.  Upon any termination of Executive&#8217;s employment for any reason, except as may otherwise be requested </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by the Company in writing and agreed upon in writing by Executive, Executive shall be deemed to have resigned from any and all directorships, committee memberships, and any other positions Executive holds with the Company or any other member of the Company Group and hereby agrees to execute any documents that the Company (or any member of the Company Group) determines necessary to effectuate such resignations.  Notwithstanding anything herein to the contrary, the payment (or commencement of a series of payments) hereunder of any &#8220;nonqualified deferred compensation&#8221; (within the meaning of Section&#160;409A of the Code) upon a termination of employment shall be delayed until such time as Executive has also undergone a &#8220;separation from service&#8221; as defined in Treas. Reg.&#160;1.409A-1(h), at which time such nonqualified deferred compensation (calculated as of the date of Executive&#8217;s termination of employment hereunder) shall be paid (or commence to be paid) to Executive on the schedule set forth in this Section 8 as if Executive had undergone such termination of employment (under the same circumstances) on the date of Executive&#8217;s ultimate &#8220;separation from service.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination Due to Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment shall terminate automatically upon Executive&#8217;s death.  The Company may terminate Executive&#8217;s employment immediately upon the occurrence of a Disability, such termination to be effective upon Executive&#8217;s receipt of written notice of such termination.  Upon Executive&#8217;s death or in the event that Executive&#8217;s employment is terminated due to Executive&#8217;s Disability, Executive or Executive&#8217;s estate or Executive&#8217;s beneficiaries, as the case may be, shall be entitled to&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Accrued Obligations&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Any unpaid Annual Bonus in respect of any completed fiscal year that has ended prior to the date of such termination, if any, which amount shall be paid at such time annual bonuses are paid to other senior executives of the Company, but in no event later than the date that is 2&#189; months following the last day of the fiscal year in which such termination occurred&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">Subject to achievement of the applicable performance objectives for the fiscal year of the Company in which Executive&#8217;s termination occurs, as determined by the Compensation Committee, payment of the Annual Bonus that would otherwise have been earned in respect of the fiscal year in which such termination occurred, pro-rated to reflect the number of days Executive was employed during such fiscal year, such amount to be paid at the same time it would otherwise be paid to Executive had no termination occurred, but in no event later than the date that is 2&#189; months following the last day of the fiscal year of the Company in which such termination occurred.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following Executive&#8217;s death or a termination of Executive&#8217;s employment by reason of a Disability, except as set forth in this Section 8(b), Executive shall have no further rights to any compensation or any other benefits under this Agreement&#59; provided, however that Executive shall remain entitled to any rights, compensation and benefits under the Company&#8217;s directors and officers insurance policies and under the Indemnification Agreement and By-Laws.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by the Company with Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Company may terminate Executive&#8217;s employment at any time with Cause, effective upon Executive&#8217;s receipt of written notice of such termination, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, to be effective, such written notice must be provided to Executive within sixty (60) days of the Board having actual knowledge of the occurrence of such event and further provided that, with respect to any Cause termination relying on clauses (ii), (vi), or (vii) of the definition of Cause set forth in Section 1(f) hereof, to the extent that such act or acts or failure or failures to act are curable, the Board shall provide Executive with written notice of the Company&#8217;s intention to terminate Executive with Cause, such notice to state in detail the particular act or acts or failure or failures to act that constitute the grounds on which the proposed termination with Cause is based and to provide Executive with ten (10) days to cure the particular act or acts or failure or failures to act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and such termination shall be effective at the expiration of the Cure Period unless Executive has fully cured such act or acts or failure or failures to act that give rise to Cause during such Cure Period.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">In the event that the Company terminates Executive&#8217;s employment with Cause, Executive shall be entitled only to the Accrued Obligations.  Following such termination of Executive&#8217;s employment with Cause, except as set forth in this Section 8(c)(ii), Executive shall have no further rights to any compensation or any other benefits under this Agreement&#59; provided, however that Executive shall remain entitled to any rights, compensation and benefits under the Company&#8217;s directors and officers insurance policies and under the Indemnification Agreement and By-Laws.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by the Company without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may terminate Executive&#8217;s employment at any time without Cause, effective upon Executive&#8217;s receipt of written notice of such termination.  In the event that Executive&#8217;s employment is terminated by the Company without Cause (other than due to death or Disability), Executive shall be entitled to&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Accrued Obligations&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Any unpaid Annual Bonus in respect of any completed fiscal year that has ended prior to the date of such termination, which amount shall be paid at such time annual bonuses are paid to other senior executives of the Company, but in no event later than the date that is 2&#189; months following the last day of the fiscal year in which such termination occurred&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">Subject to achievement of the applicable performance objectives for the fiscal year of the Company in which Executive&#8217;s termination occurs, as determined by the Compensation Committee, payment of the Annual Bonus that would otherwise have been earned in respect of the fiscal year in which such termination occurred, pro-rated to reflect the number of days Executive was employed during such fiscal year, such amount to be paid at the same time it would otherwise be paid to Executive had no termination occurred, but in no event later than the date that is 2&#189; months following the last day of the fiscal year of the Company in which such termination occurred&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Continued payment of Base Salary during the Severance Term, payable in accordance with the Company&#8217;s regular payroll practices&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding any provision to the contrary in any stock option agreement or any equity plan maintained by the Company, all stock options held by Executive as of the date of Executive&#8217;s termination of employment shall remain exercisable until the earlier to occur of (a) the expiration date of such stock option and (b) the twelve (12) month anniversary of Executive&#8217;s termination&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">To the extent permitted by applicable law without any penalty to Executive or any member of the Company Group and subject to (1) Company&#8217;s obligations under the American Rescue Plan Act of 2021 and (2) Executive&#8217;s election of COBRA continuation coverage under the Company&#8217;s group health plan and Executive&#8217;s payment of all COBRA continuation coverage insurance premiums, on the first regularly scheduled payroll date of each month of the Severance Term, the Company will reimburse Executive an amount equal to the &#8220;applicable percentage&#8221; of the monthly COBRA premium cost&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the COBRA payments pursuant to this clause (vi) shall cease earlier than the expiration of the Severance Term in the event that Executive becomes eligible to receive any health benefits, including through a spouse&#8217;s employer, during the Severance Term and&#47;or if Executive violates Executive&#8217;s obligations under the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Executive violates Executive&#8217;s obligations under the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> then the Company&#8217;s reimbursement of such COBRA premiums shall cease immediately upon the Company&#8217;s determination that Executive has violated the obligations referenced in this sentence. If Executive becomes eligible to receive any health benefits, including through a spouse&#8217;s employer, during the Severance Term, Executive shall be required to notify the Company of such within 15 days of Executive becoming eligible for such alternate health insurance coverage. Upon receipt of such notification, the Company shall cease providing Executive any further reimbursement of COBRA premiums.  For purposes hereof, the &#8220;applicable percentage&#8221; shall be the percentage of Executive&#8217;s health care premium costs covered by the Company as of the date of termination.  Amounts paid by the Company will be taxable to the extent required to avoid adverse consequences to Executive or the Company under either Section 105(h) of the Code or the Patient Protection and Affordable Care Act of 2010. At the end of the Severance Term, Executive shall receive no further reimbursement from the Company of any COBRA continuation coverage insurance premiums that Executive pays for the duration of the COBRA continuation period that Executive may be eligible for under applicable state and federal law. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">So long as Executive has received the first monthly installment of the Severance Payment, notwithstanding the foregoing, the payments and benefits described in clauses (ii), (iii), (iv), (v) and (vi) above shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, in the event that Executive breaches any provision of the Non-Interference Agreement.  Executive agrees that in the event Executive has breached the Non-Interference Agreement and Company has ceased making Severance Payments, that so long has Executive has received the first installment of the Severance Benefits, the Release of Claims attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto shall remain in full force and effect notwithstanding the cessation of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">severance payments by Company as a result of Executive&#8217;s breach of the Non-Interference Agreement.  Following such termination of Executive&#8217;s employment by the Company without Cause, except as set forth in this Section 8(d), Executive shall have no further rights to any compensation or any other benefits under this Agreement.  For the avoidance of doubt, Executive&#8217;s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of the Severance Benefits&#59; provided, however that Executive shall remain entitled to any rights, compensation and benefits under the Company&#8217;s directors and officers insurance policies and under the Indemnification Agreement and By-Laws.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by Executive with Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive may terminate Executive&#8217;s employment with Good Reason by providing the Company written notice setting forth in reasonable specificity the event that constitutes Good Reason, which written notice, to be effective, must be provided to the Company within sixty (60) days of the occurrence of such event.  Said notice shall state in detail the particular act or acts or failure or failures to act that constitute the grounds on which the proposed termination for Good Reason is based and shall provide the Company with a Cure Period (as defined in Section 8(c)(i) above), and such termination shall be effective at the expiration of the Cure Period unless the Company has fully cured such act or acts or failure or failures to act that give rise to Good Reason during such Cure Period. In the event of termination with Good Reason, Executive shall be entitled to the same payments and benefits as provided in Section 8(d) hereof for a termination by the Company without Cause, subject to the same conditions on payment and benefits as described in Section 8(d) hereof.  Following such termination of Executive&#8217;s employment by Executive with Good Reason, except as set forth in this Section 8(e), Executive shall have no further rights to any compensation or any other benefits under this Agreement.  For the avoidance of doubt, Executive&#8217;s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of the Severance Benefits&#59; provided, however that Executive shall remain entitled to any rights, compensation and benefits under the Company&#8217;s directors and officers insurance policies and under the Indemnification Agreement and By-Laws.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">So long as Executive has received the first monthly installment of the Severance Payment, notwithstanding the foregoing, the payments and benefits described in clauses (ii), (iii), (iv), (v) and (vi) of Section 8(d) above that would otherwise be due and owing under this Section (e) shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, in the event that Executive breaches any provision of the Non-Interference Agreement. Executive agrees that in the event Executive has breached the Non-Interference Agreement and Company has ceased making Severance Payments, that so long has Executive has received the first installment of the Severance Benefits, the Release of Claims attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto shall remain in full force and effect notwithstanding the cessation of severance payments by Company as a result of Executive&#8217;s breach of the Non-Interference Agreement.  Following such termination of Executive&#8217;s employment by the Executive with Good Reason, except as set forth in Section 8(d), Executive shall have no further rights to any compensation or any other benefits under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Termination by Executive without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive may terminate Executive&#8217;s employment without Good Reason by providing the Company thirty (30) days&#8217; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">written notice of such termination.  In the event of a termination of employment by Executive under this Section 8(f), Executive shall be entitled only to the Accrued Obligations.  In the event of termination of Executive&#8217;s employment under this Section 8(f), the Company may, in its sole and absolute discretion, by written notice accelerate such date of termination without changing the characterization of such termination as a termination by Executive without Good Reason.  Following such termination of Executive&#8217;s employment by Executive without Good Reason, except as set forth in this Section 8(f), Executive shall have no further rights to any compensation or any other benefits under this Agreement&#59; provided, however that Executive shall remain entitled to any rights, compensation and benefits under the Company&#8217;s directors and officers insurance policies and under the Indemnification Agreement and By-Laws.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provision herein to the contrary, the payment of any amount or provision of any benefit pursuant to subsection (b), (d), or (e) of this Section 8 (other than the Accrued Obligations) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be conditioned upon Executive&#8217;s execution, delivery to the Company, and non-revocation of the Release of Claims attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto (and the expiration of any revocation period contained in such Release of Claims) within sixty (60) days following the date of Executive&#8217;s termination of employment hereunder.  If Executive fails to execute the Release of Claims in such a timely manner so as to permit any revocation period to expire prior to the end of such sixty (60) day period, or timely revokes Executive&#8217;s acceptance of such release following its execution, Executive shall not be entitled to any of the Severance Benefits.  Further, (i)&#160;to the extent that any of the Severance Benefits constitutes &#8220;nonqualified deferred compensation&#8221; for purposes of Section&#160;409A of the Code, any payment of any amount or provision of any benefit otherwise scheduled to occur prior to the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day following the date of Executive&#8217;s termination of employment hereunder, but for the condition on executing the Release of Claims as set forth herein, shall not be made until the first regularly scheduled payroll date following such sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day and (ii)&#160;to the extent that any of the Severance Benefits do not constitute &#8220;nonqualified deferred compensation&#8221; for purposes of Section&#160;409A of the Code, any payment of any amount or provision of any benefit otherwise scheduled to occur following the date of Executive&#8217;s termination of employment hereunder, but for the condition on executing the Release of Claims as set forth herein, shall not be made until the first regularly scheduled payroll date following the date the Release of Claims is timely executed and the applicable revocation period has ended, after which, in each case, any remaining Severance Benefits shall thereafter be provided to Executive according to the applicable schedule set forth herein.  For the avoidance of doubt, in the event of a termination due to Executive&#8217;s death or Disability, Executive&#8217;s obligations herein to execute and not revoke the Release of Claims may be satisfied on Executive&#8217;s behalf by Executive&#8217;s estate or a person having legal power of attorney over Executive&#8217;s affairs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Non-Interference Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a condition of, and prior to commencement of, Executive&#8217;s employment with the Company, Executive shall have executed and delivered to the Company the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and otherwise referenced to in this Agreement as the Non-Interference Agreement.   The parties hereto acknowledge and agree that this Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be considered separate contracts, and the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will survive the termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Representations and Warranties of Executive.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive represents and warrants to the Company that&#8212;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive is entering into this Agreement voluntarily and that Executive&#8217;s employment hereunder and compliance with the terms and conditions hereof will not conflict with or result in the breach by Executive of any agreement to which Executive is a party or by which Executive may be bound&#59;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Executive has not violated, and in connection with Executive&#8217;s employment with the Company will not violate, any non-solicitation, non-competition, or other similar covenant or agreement of a prior employer by which Executive is or may be bound&#59; and</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">in connection with Executive&#8217;s employment with the Company, Executive has not used and will not use any confidential or proprietary information Executive may have obtained in connection with employment with any prior employer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Taxes.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may withhold from any payments made under this Agreement all applicable taxes, including, but not limited to, income, employment, and social insurance taxes, as shall be required by law.  Executive acknowledges and represents that the Company has not provided any tax advice to Executive in connection with this Agreement and that Executive has been advised by the Company to seek tax advice from Executive&#8217;s own tax advisors regarding this Agreement and payments that may be made to Executive pursuant to this Agreement, including specifically, the application of the provisions of Section&#160;409A of the Code to such payments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Set Off&#59; Mitigation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company&#8217;s obligation to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to set-off, counterclaim, and recoupment of amounts owed by Executive to any member of the Company Group&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that (i) prior to exercising any right of set-off, counterclaim, or recoupment, the Company shall provide Executive with written notice setting forth, in detail, the facts on which it relies to support its claim of set-off, counterclaim, or recoupment&#59; (ii) to the extent any amount so subject to set-off, counterclaim, or recoupment is payable in installments hereunder, such set-off, counterclaim, or recoupment shall not modify the applicable payment date of any installment&#59; and (iii) to the extent an obligation cannot be satisfied by reduction of a single installment payment, any portion not satisfied shall remain an outstanding obligation of Executive and shall be applied to the next installment only at such time the installment is otherwise payable pursuant to the specified payment schedule.  Executive shall not be required to mitigate the amount of any payment or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefit provided pursuant to this Agreement by seeking other employment or otherwise, and except as provided in Section 8(d)(vi) hereof, the amount of any payment or benefit provided for pursuant to this Agreement shall not be reduced by any compensation earned as a result of Executive&#8217;s other employment or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Additional Section&#160;409A Provisions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision in this Agreement to the contrary&#8212;</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Any payment otherwise required to be made hereunder to Executive at any date as a result of the termination of Executive&#8217;s employment shall be delayed for such period of time as may be necessary to meet the requirements of Section&#160;409A(a)(2)(B)(i) of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  On the first business day following the expiration of the Delay Period, Executive shall be paid, in a single cash lump sum, an amount equal to the aggregate amount of all payments delayed pursuant to the preceding sentence, and any remaining payments not so delayed shall continue to be paid pursuant to the payment schedule set forth herein.  </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section&#160;409A of the Code.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">To the extent that any right to reimbursement of expenses or payment of any benefit in-kind under this Agreement constitutes nonqualified deferred compensation (within the meaning of Section&#160;409A of the Code), (i)&#160;any such expense reimbursement shall be made by the Company no later than the last day of the taxable year following the taxable year in which such expense was incurred by Executive, (ii)&#160;the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (iii)&#160;the amount of expenses eligible for reimbursement or in-kind benefits provided during any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable year&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the foregoing clause (iii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The payments and benefits provided hereunder are intended to be structured in a manner to avoid the implication of any penalty taxes under Section&#160;409A of the Code and the terms of this Agreement and all such payments and benefits shall be interpreted in accordance with such intent. In no event whatsoever shall the Company or any of its affiliates (including, without limitation, the Company) be liable for any additional tax, interest, or penalties that may be imposed on Executive as a result of Section&#160;409A of the Code or any damages for failing to comply with Section&#160;409A of the Code (other than for withholding obligations or other obligations applicable to employers, if any, under Section&#160;409A of the Code).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Golden Parachute Tax Provision. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If there is a change in ownership or control of the Company that would cause any payment or distribution by the Company or any other Person or entity to Executive or for Executive&#8217;s benefit (whether paid or payable or distributed or distributable pursuant to the terms </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of this Agreement or otherwise) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be subject to the excise tax imposed by Section&#160;4999 of the Code (such excise tax, together with any interest or penalties incurred by Executive with respect to such excise tax, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then Executive will receive the greatest of the following, whichever gives Executive the highest net after-tax amount (after taking into account federal, state, local and social security taxes)&#58; (a) the Payments or (b) one dollar less than the amount of the Payments that would subject Executive to the Excise Tax (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Safe Harbor Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).&#160; If a reduction in the Payments is necessary so that the Payments equal the Safe Harbor Amount and none of the Payments constitutes nonqualified deferred compensation (within the meaning of Section 409A of the Code), then the reduction shall occur in the manner Executive elects in writing prior to the date of payment.&#160; If any Payment constitutes nonqualified deferred compensation or if Executive fails to elect an order, then the Payments to be reduced will be determined in a manner which has the least economic cost to Executive and, to the extent the economic cost is equivalent, will be reduced in the inverse order of when payment would have been made to Executive, until the reduction is achieved.&#160; All determinations required to be made under this Section 14, including whether and when the Safe Harbor Amount is required and the amount of the reduction of the Payments and the assumptions to be utilized in arriving at such determination, shall be made by a certified public accounting firm designated by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).&#160; All fees and expenses of the Accounting Firm shall be borne solely by the Company.&#160; Any determination by the Accounting Firm shall be binding upon Company and Executive.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Clawback.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All payments made pursuant to this Agreement are subject to the &#8220;clawback&#8221; obligations of Section&#160;954 of the Dodd-Frank Wall Street Reform and Consumer Act, as may be amended from time to time, and any other &#8220;clawback&#8221; obligations pursuant to applicable law, rules, and regulations, including, without limitation, the Company&#8217;s Clawback Policy as may be in effect from time to time and applicable to Executive.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive shall be indemnified and held harmless pursuant to the terms and conditions set forth in the Indemnification Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Successors and Assigns&#59; No Third-Party Beneficiaries.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">The Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall inure to the benefit of the Company and its respective successors and assigns.  Neither this Agreement nor any of the rights, obligations, or interests arising hereunder may be assigned by the Company to a Person (other than another member of the Company Group, or its or their respective successors) without Executive&#8217;s prior written consent (which shall not be unreasonably withheld, delayed, or conditioned)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that in the event of a sale of all or substantially all of the assets of the Company or any direct or indirect division or subsidiary thereof to which Executive&#8217;s employment primarily relates, the Company may provide that this Agreement will be assigned to, and assumed by, the acquiror of such assets, it being agreed that in such circumstances, Executive&#8217;s consent will not be required in connection therewith.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive&#8217;s rights and obligations under this Agreement shall not be transferable by Executive by assignment or otherwise, without the prior written consent of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if Executive shall die, all amounts then payable to Executive hereunder shall be paid in accordance with the terms of this Agreement to Executive&#8217;s devisee, legatee, or other designee, or if there be no such designee, to Executive&#8217;s estate.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise set forth in Section 8(b) or Section 17(b) hereof, nothing expressed or referred to in this Agreement will be construed to give any Person other than the Company, the other members of the Company Group, and Executive any legal or equitable right, remedy, or claim under or with respect to this Agreement or any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Waiver and Amendments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any waiver, alteration, amendment, or modification of any of the terms of this Agreement shall be valid only if made in writing and signed by each of the parties hereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any such waiver, alteration, amendment, or modification must be consented to on the Company&#8217;s behalf by the Board.  No waiver by either of the parties hereto of their rights hereunder shall be deemed to constitute a waiver with respect to any subsequent occurrences or transactions hereunder unless such waiver specifically states that it is to be construed as a continuing waiver.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Severability.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any covenants or such other provisions of this Agreement are found to be invalid or unenforceable by a final determination of a court of competent jurisdiction, (a)&#160;the remaining terms and provisions hereof shall be unimpaired, and (b)&#160;the invalid or unenforceable term or provision hereof shall be deemed replaced by a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 20.&#160;&#160;&#160;&#160;Arbitration of Disputes</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive and the Company agree to utilize binding individual arbitration to resolve all disputes that might arise out of or be related in any way to Executive&#8217;s employment by the Company. Such disputes include, but are not limited to, claims Executive might bring against the Company for wrongful termination, discrimination, harassment, retaliation, breach of contract, wage and hour violations, and torts such as invasion of privacy, assault and battery, or defamation.  Such disputes also include claims that the Company might bring against Executive such as, for example, theft of money or trade secrets, breach of a confidentiality agreement, or breach of a contract.  Executive and the Company each specifically waive our respective rights to bring such claims against the other in a court of law and to have a trial by jury.  </font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The only exceptions to binding arbitration shall be for claims arising under the National Labor Relations Act which are brought before the National Labor Relations Board, claims for medical and disability benefits under state workers&#8217; compensation law, claims for unemployment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">insurance, or other claims that are not subject to arbitration under law.  The Company shall also have the right to seek a temporary restraining order and&#47;or preliminary injunction to enforce the terms of the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> until such time as an arbitrator can be appointed to assume jurisdiction of any dispute involving the Non-Interference Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement. Moreover, nothing herein shall prevent Executive from filing a charge or complaint with the United States Equal Employment Opportunity Commission or a similar state or local agency that allows me to file an administrative charge or complaint.  Once the agency&#8217;s proceedings are completed, however, if Executive wishes to pursue the matter further Executive understands that Executive must do so under this Agreement.   </font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive&#8217;s agreement to arbitrate claims against the Company includes claims Executive might bring against the Company&#8217;s parent, subsidiary, affiliated or client entities as well as against owners, directors, officers, managers, employees, agents, contractors, attorneys, benefit plan administrators, and insurers of the Company or of its parent, subsidiary, affiliated or client entities.  Executive also agrees to arbitrate claims against any person or entity Executive alleges to be a joint employer with the Company.</font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive and the Company agree that any claims we might pursue against the other in arbitration under this Agreement shall be brought in the individual capacity of Executive or the Company.  This Agreement shall not be construed to allow or permit the consolidation or joinder of claims of other claimants, or to permit such claims to proceed as a class or collective action.  No arbitrator shall have the authority under this Agreement to order any such class or collective action.  Any dispute regarding the validity, scope or enforceability of this Agreement, or concerning the arbitrability of a particular claim, shall be resolved by a court, not by the arbitrator. Executive agrees to waive any substantive or procedural rights that Executive may have to bring or participate in an action brought on a class or collective basis.  </font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Executive wishes to bring a claim to arbitration under this Agreement, Executive understands that Executive must provide a written statement of Executive&#8217;s claim to the Head of the Company&#8217;s People Department.  Executive understands that Executive has the right to be represented by an attorney in the arbitration of any claim under this Agreement, but it is not required that Executive have an attorney.  Executive further understands that Executive must present any claim in arbitration before the statute of limitations expires for that type of claim. </font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At the beginning of any arbitration process under this Agreement, Executive and the Company will need to select an arbitrator by mutual agreement.  Such an arbitrator shall be a retired state or federal court judge in the state in which the dispute arose, or another qualified and impartial person that Executive and the Company decide upon.  In the event we cannot agree on the selection of an arbitrator, Executive and the Company will select an alternative dispute resolution provider and request from that provider a list of an odd number of potential arbitrators.  From that list we will alternatively strike arbitrators, with the Company going first, until one arbitrator is left.  That arbitrator shall be the arbitrator who will hear our case. If Executive and the Company cannot agree on an alternative dispute resolution provider, an arbitrator will be appointed according to law.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any arbitration proceeding under this Agreement shall proceed under and be governed by the Federal Arbitration Act, in conformity with the arbitration law of the state in which the dispute arose.  In any arbitration proceeding under this Agreement, all rules of pleading under the Federal Rules of Civil Procedure, the Federal Rules of Evidence, and all rights to resolution of the dispute by means of motions for summary judgment or judgment on the pleadings shall apply and be observed unless Executive and the Company agree otherwise.  The arbitrator shall have the immunity of a judicial officer from civil liability when acting in the capacity of an arbitrator, which immunity supplements any other existing immunity.  Likewise, all communications during or in connection with the arbitration proceedings shall be privileged.  The arbitrator&#8217;s award(s) shall include the arbitrator&#8217;s written reasoned opinion.  Resolution of all disputes shall be based solely upon the law governing the claims and defenses pleaded, and the arbitrator may not invoke any basis (including but not limited to, notions of &#8220;just cause&#8221;) other than such controlling law. </font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will pay the arbitrator&#8217;s fees and other costs relating to the arbitration forum but Executive and the Company will be responsible for our own costs and for our attorneys&#8217; fees should we choose to be represented by counsel, unless the arbitrator shifts one party&#8217;s costs and attorneys&#8217; fees to the other party in accordance with applicable law.</font></div><div style="margin-bottom:14.85pt;padding-right:0.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any term or provision or any portion of this arbitration provision is deemed invalid or unenforceable, it shall be severed and the remainder of this Agreement shall be enforceable.  Under no circumstances shall this Agreement be construed to allow arbitration on a class, collective, or other similar basis, however.</font></div><div style="margin-bottom:13.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive confirms that Executive has had time to read this arbitration of disputes provision and ask the Company&#8217;s representative any questions Executive had about the arbitration of disputes provision prior to signing this Agreement.  Executive further confirms that Executive is signing this Agreement voluntarily and not under any duress or threat of negative consequences for not signing this Agreement. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE&#8217;S SIGNATURE BELOW CONFIRMS THE FACT THAT EXECUTIVE HAS READ, UNDERSTANDS, AND VOLUNTARILY AGREES TO BE LEGALLY BOUND TO ALL OF THE ABOVE TERMS OF THIS SECTION 20.  EXECUTIVE FURTHER UNDERSTAND THAT THIS SECTION 20 REQUIRES THE COMPANY AND EXECUTIVE TO ARBITRATE ANY AND ALL DISPUTES THAT ARISE OUT OF EXECUTIVE&#8217;S EMPLOYMENT, AND THAT EXECUTIVE AND THE COMPANY ARE GIVING UP OUR RIGHTS TO A TRIAL BY JURY.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Governing Law and Jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXCEPT WHERE PREEMPTED BY FEDERAL LAW, THE VALIDITY, INTERPRETATION, CONSTRUCTION, AND PERFORMANCE OF THIS AGREEMENT IS GOVERNED BY AND IS TO BE CONSTRUED UNDER THE LAWS OF THE STATE OF UTAH APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Notices.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Place of Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Every notice or other communication relating to this Agreement shall be in writing, and shall be mailed to or delivered to the party for whom or which it is intended at such address as may from time to time be designated by it in a notice mailed or delivered to the other party as herein provided&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that unless and until some other address be so designated, all notices and communications by Executive to the Company shall be mailed or delivered to the Company at its principal executive office, and all notices and communications by the Company to Executive may be given to Executive personally or may be mailed to Executive at Executive&#8217;s last known address, as reflected in the Company&#8217;s records.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Date of Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice so addressed shall be deemed to be given or received (i)&#160;if delivered by hand, on the date of such delivery, (ii)&#160;if mailed by courier or by overnight mail, on the first business day following the date of such mailing, and (iii)&#160;if mailed by registered or certified mail, on the third business day after the date of such mailing.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Section Headings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The headings of the sections and subsections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part thereof or affect the meaning or interpretation of this Agreement or of any term or provision hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Entire Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, together with any documents referenced within this Agreement and any exhibits attached hereto and Executive&#8217;s Indemnification Agreement,  constitutes the entire understanding and agreement of the parties hereto regarding the employment of Executive during the Term of this Agreement.  This Agreement supersedes all prior negotiations, discussions, correspondence, communications, understandings, and agreements between the parties relating to the subject matter of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Survival of Operative Sections.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon any termination of Executive&#8217;s employment, the provisions of Section 8 through 25 of this Agreement (together with any related definitions set forth in Section 1 hereof) shall survive to the extent necessary to give effect to the provisions thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.7pt">Counterparts.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.  The execution of this Agreement may be by actual signature or by signature delivered by facsimile or by e-mail as a portable document format (.pdf) file or image file attachment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signatures to appear on the following page(s).&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="id53062a59f9b4124964bc1e63c8d5a7d_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.</font></div><div style="margin-bottom:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HEALTHEQUITY, INC.</font></div><div style="margin-bottom:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Delano Ladd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________<br>By&#58;  Delano Ladd<br>Title&#58; EVP and General Counsel</font></div><div style="margin-bottom:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE</font></div><div style="margin-bottom:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott R. Cutler</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________<br>Scott R. Cutler</font></div><div id="id53062a59f9b4124964bc1e63c8d5a7d_7"></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cutler-hqyindemnificationa.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i057e64705caa436ebd203960a62cdb8d_1"></div><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INDEMNIFICATION AGREEMENT</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Indemnification Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is dated as of November 11, 2024, and is between HealthEquity, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Scott R. Cutler (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Individuals are reluctant to serve as directors, officers or executives of corporations or in certain other capacities unless they are provided with adequate protection through insurance and indemnification against the risks of claims and actions against them arising out of such service.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Indemnitee&#8217;s service to the Company provides or will provide substantial benefits to the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Indemnitee does not regard the protection currently provided by applicable law, the Company&#8217;s governing documents and any insurance as adequate under the present circumstances, and Indemnitee may not be willing to serve or continue to serve as a director or officer without additional protection.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;In order to induce Indemnitee to serve or to continue to serve as a director or officer or executive of the Company, it is reasonable, prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee to the fullest extent permitted by applicable law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E.&#160;&#160;&#160;&#160;This Agreement is a supplement to and in furtherance of the indemnification provided in the Company&#8217;s certificate of incorporation and bylaws, and any resolutions adopted pursuant thereto, as well as any rights of Indemnitee under any directors&#8217; and officers&#8217; liability insurance policy, and this Agreement shall not be deemed a substitute therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties therefore agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Definitions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Associate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as in effect on the date of this Agreement&#59; provided, however, that no Person who is a director or officer of the Company shall be deemed an Affiliate or an Associate of any other director or officer of the Company solely as a result of his or her position as director or officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">A Person shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of, and shall be deemed to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Beneficially Own</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of, any securities that such Person or any of such Person&#8217;s Affiliates or Associates, directly or indirectly, Beneficially Owns (as determined pursuant to Rule 13d-3 of the Rules under the Exchange Act, as in effect on the date of this Agreement). Notwithstanding the foregoing, no Person engaged in business as an underwriter of securities shall be deemed the Beneficial Owner of any securities acquired through such Person&#8217;s participation as an underwriter in good faith in a firm commitment underwriting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt"> A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.63pt;text-decoration:underline">Acquisition of Stock by Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Person is or becomes the Beneficial Owner (as defined above), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, provided that a Change of Control shall be deemed to have occurred if subsequent to such reduction such Person becomes the Beneficial Owner, directly or indirectly, of any additional securities of the Company conferring upon such Person any additional voting power of at least 1% of the combined voting power of the Company&#8217;s then outstanding securities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.58pt;text-decoration:underline">Change in Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in Sections 2(c)(i), 2(c)(iii) or 2(c)(iv)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:1.53pt;text-decoration:underline">Corporate Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The effective date of a merger or consolidation of the Company with any other entity&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:2.13pt;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale, lease, exchange or other transfer by the Company, in one or a series of related transactions, of all or substantially all of the Company&#8217;s assets&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.18pt;text-decoration:underline">Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the  Exchange Act whether or not the Company is then subject to such reporting requirement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in no event shall a Change in Control shall be deemed to occur (i) as a result of a Holding Company Reorganization or (ii) if Indemnitee is part of a &#8220;group&#8221; within the meaning of Section 13(d)(3) of the Exchange Act, as in effect on the date of this Agreement, that consummates what would otherwise be a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the General Corporation Law of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Disinterested Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Company and any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; include all attorneys&#8217; fees, retainers, court costs, transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include (i)&#160;Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond or other appeal bond or their equivalent, and (ii)&#160;for purposes of Section 12 of this Agreement, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, the certificate of incorporation or by-laws or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company. For the purpose of indemnification hereunder, the term &#8220;Expenses&#8221; shall not include amounts paid in settlement by Indemnitee or the amount of judgments, penalties or fines against Indemnitee, in each case, in connection with any derivative actions, except to the extent determined by the Delaware Court of Chancery as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:25.63pt">&#8220;Holding Company Reorganization&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means any reorganization, merger, consolidation or other transaction which would result in the voting securities of the Company outstanding immediately prior to such reorganization, merger, consolidation or other transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or successor entity) more than 50% of the combined voting power of the voting securities of the surviving or successor entity outstanding immediately after such reorganization, merger, consolidation or other transaction and with the power to elect at least a majority of the board of directors or other governing body of such surviving or successor entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a law firm, or a partner or member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i)&#160;the Company, any subsidiary of the Company, or Indemnitee in any matter material to either such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii)&#160;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or proceeding, or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, investigative, regulatory or investigative nature, and whether formal or informal, including any appeal therefrom and including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or otherwise by reason of (i)&#160;the fact that Indemnitee is or was a director or officer of the Company, (ii)&#160;any action taken </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by Indemnitee or any action or inaction on Indemnitee&#8217;s part while acting as a director or officer of the Company, or (iii)&#160;the fact that he or she is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">Reference to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">other enterprises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall include employee benefit plans&#59; references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">fines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall include any excise taxes assessed on a person with respect to any employee benefit plan&#59; references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">serving at the request of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries&#59; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">not opposed to the best interests of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; as referred to in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Indemnity in Third-Party Proceedings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company shall indemnify Indemnitee in accordance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> if, by reason of his or her Corporate Status, Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Indemnity in Proceedings by or in the Right of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company shall indemnify Indemnitee in accordance with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> if, by reason of his or her Corporate Status, Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court of Chancery shall deem proper.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> To the extent that Indemnitee, by reason of his or her Corporate Status, is a party to or a participant in any Proceeding and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith, and, to the extent permitted by applicable law, if Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, in defense of one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indemnitee or on Indemnitee&#8217;s behalf in connection with each successfully resolved claim, issue or matter. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> limits the Indemnitee&#8217;s right under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any other Section of this Agreement, to indemnification to the fullest extent permitted by applicable law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Indemnification for Expenses of a Witness.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> To the extent that Indemnitee is, by reason of his or her Corporate Status, a witness, or is or was made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&#8217;s behalf in connection therewith.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Additional Indemnification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Notwithstanding any limitation in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee, by reason of his or her Corporate Status, is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with the Proceeding or any claim, issue or matter therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">For purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above, the meaning of the phrase &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">to the fullest extent permitted by applicable law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall include, but not be limited to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.63pt">the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL&#59; and</font></div><div style="text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.58pt">the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Exclusions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any Proceeding (or any part of any Proceeding)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">for which payment has actually been made to or on behalf of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid, and except as may otherwise be agreed between the Company, on the one hand, and Indemnitee or another indemnitor of Indemnitee, on the other hand&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">for an accounting or disgorgement of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&#160;16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements)&#59; provided that the Company shall advance Expenses in connection with Indemnitee&#8217;s defense of a claim under Section 16(b), which advances shall be repaid to the Company if it is ultimately determined that Indemnitee is not entitled to indemnification of such Expenses.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Rule 10D of the Exchange Act or  Section&#160;304 of the Sarbanes-Oxley Act of 2002 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sarbanes-Oxley Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section&#160;306 of the Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, agents or other indemnitees, unless (i)&#160;the Company&#8217;s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii)&#160;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii)&#160;otherwise authorized in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement or (iv)&#160;otherwise required by applicable law&#59; provided, however, that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not apply to counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee&#59; or</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">if prohibited by applicable law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Advances of Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding in which Indemnitee is, or is threatened to be made, a party to or a participant in by reason of Indemnitee&#8217;s Corporate Status, and such advancement shall be made as soon as reasonably practicable, but in any event no later than 20 days, after the receipt by the Company of a written statement or statements from Indemnitee requesting such advances from time to time (which shall include invoices received by Indemnitee in connection with such Expenses or otherwise reasonably evidence the Expenses incurred by Indemnitee, but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice). Advances shall be unsecured and interest free and made without regard to Indemnitee&#8217;s ability to repay such advances. Indemnitee hereby undertakes to repay any advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not apply to the extent advancement is prohibited by law and shall not apply to any Proceeding for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement prior to a determination that Indemnitee is not entitled to be indemnified by the Company.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Procedures for Notification and Defense of Claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Indemnitee shall notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment or other document relating to any Proceeding or any matter which may be subject to indemnification covered hereunder with respect to which Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee thereof. The written notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts underlying the Proceeding. The failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors&#8217; and officers&#8217; liability insurance in effect, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all reasonably necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. Notwithstanding the Company&#8217;s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee&#8217;s counsel to the extent (i)&#160;the employment of counsel by Indemnitee is authorized by the Company, (ii)&#160;counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense such that Indemnitee needs to be separately represented, (iii)&#160;the Company is not financially or legally able to perform its indemnification obligations, (iv)&#160;the Company shall not have retained, or shall not continue to retain, such counsel to defend such Proceeding, or (v) a Change in Control shall have occurred. The Company shall have the right to conduct such defense as it sees fit in its sole discretion. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee&#8217;s personal expense. The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate, and the Company shall likewise give Indemnitee such information and cooperation in connection with the Proceeding as may be reasonably appropriate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) without the Company&#8217;s prior written consent, which shall not be unreasonably withheld. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Procedures upon Application for Indemnification. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the Proceeding. The Company shall, promptly after receipt of such a request for indemnification, advise the board of directors that Indemnitee has requested indemnification. Any delay in providing the request will not relieve the Company from its obligations under this Agreement, except to the extent such failure is prejudicial.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Upon written request by Indemnitee for indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above, a determination with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case&#58; (x) if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, by Independent Counsel in a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">written opinion to the Board&#59; or (y) in any other case, (A)&#160;by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#8217;s board of directors, (B)&#160;by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company&#8217;s board of directors, (C)&#160;if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company&#8217;s board of directors, a copy of which shall be delivered to Indemnitee or (D)&#160;if so directed by the Company&#8217;s board of directors, by the stockholders of the Company. If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Independent Counsel shall be selected by the Board of Directors and approved by Indemnitee&#59; provided that, if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, the Independent Counsel shall be selected by Indemnitee.  Upon either (i) failure of the board of directors to select Independent Counsel, or upon the failure of Indemnitee to so approve, if a Change in Control shall not have occurred, or (ii) if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, upon the failure of Indemnitee to select Independent Counsel, such Independent Counsel shall be selected by the Court of Chancery of the State of Delaware or such other person or body as the Indemnitee and the Company may agree in writing.  If the person making such determination shall determine that Indemnitee is entitled to indemnification as to part (but not all) of the application for indemnification, such person shall reasonably pro-rate such part of indemnification among such claims, issues or matters.  If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination. Indemnitee and the Company shall each cooperate with the person, persons or entity making the determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee or the Company, as the case may be, and reasonably necessary to such determination. Any costs or expenses (including attorneys&#8217; fees and disbursements) reasonably incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the fullest extent permitted by applicable law. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Presumptions and Effect of Certain Proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">nolo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in good faith on (i)&#160;the records or books of account of the Enterprise, including financial statements, (ii)&#160;information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, (iii)&#160;the advice of legal counsel for the Enterprise or its board of directors or counsel selected by any committee of the board of directors or (iv)&#160;information or records given or reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Indemnitee and the Company shall each cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee or the Company, as the case may be, and reasonably necessary to such determination.  Any Independent Counsel or member of the Board of Directors shall act reasonably and in good faith in making a determination regarding the Indemnitee&#8217;s entitlement to indemnification under this Agreement.  Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty.  In the event that any Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such Proceeding.  Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Remedies of Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below, in the event that (i)&#160;a determination is made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)&#160;advancement of Expenses is not timely made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement, (iii)&#160;no determination of entitlement to indemnification shall have been made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement within 60 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv)&#160;payment of indemnification pursuant to this Agreement is not made (A)&#160;within ten days after a determination has been made that Indemnitee is entitled to indemnification or (B)&#160;with respect to indemnification pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement, within 30 days after receipt by the Company of a written request therefor, or (v)&#160;the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by the Delaware Court of Chancery of his or her entitlement to such indemnification or advancement of Expenses. The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication in accordance with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Neither (i)&#160;the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii)&#160;an actual determination by the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, shall be a defense to an action or create a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">presumption that Indemnitee has or has not met the applicable standard of conduct. In the event that a determination shall have been made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be conducted in all respects as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">de novo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> trial, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination.  In connection with any determination (including a determination by the Court of Chancery of the State of Delaware) with respect to entitlement to indemnification hereunder, the Company shall, to the fullest extent not prohibited by law, have the burden of proving that Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be, and any decision that Indemnitee is not entitled to indemnification or advancement of Expenses must be supported by clear and convincing evidence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">To the fullest extent permissible under applicable law, the Company shall indemnify Indemnitee against all Expenses that are incurred by Indemnitee in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company to the extent Indemnitee is successful in such action, and, if requested by Indemnitee, shall (as soon as reasonably practicable, but in any event no later than 30 days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Contribution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">To the fullest extent permissible under applicable law, whether or not the indemnification provided in this Agreement is available, in respect of any threatened, pending or completed Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee.  The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">To the fullest extent permissible under applicable law, without diminishing or impairing the obligations of the Company set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall contribute to the amount of Expenses, judgments, fines, liabilities and amounts paid in settlement actually incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction from which such Proceeding arose&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the events that resulted in such expenses, judgments, fines, liabilities or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">settlement amounts, as well as any other equitable considerations which the law may require to be considered.  The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claim of contribution brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments, fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&#160;the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding&#59; and (ii)&#160;the relative fault of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with such events and transactions.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Non-exclusivity&#59; Additional Indemnification Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The rights of indemnification and contribution and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company&#8217;s certificate of incorporation or bylaws, any other agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification, contribution or advancement of Expenses than would be afforded currently under the Company&#8217;s certificate of incorporation and bylaws (as now or hereafter in effect) and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein or therein.  In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify a member of its board of directors or an officer, employee, agent or fiduciary, such change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties&#8217; rights and obligations hereunder except as set forth in Section 7(e).</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.  Notwithstanding anything in this Agreement to the contrary, the indemnification and contribution provided for in this Agreement will remain in full force and effect regardless of any investigation made by or on behalf of Indemnitee or Indemnitee&#8217;s agents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Primary Responsibility.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Company acknowledges that Indemnitee may have certain rights to indemnification and advancement of expenses provided by the fund and&#47;or certain affiliates thereof with whom Indemnitee may be affiliated (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Secondary Indemnitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Company agrees that, as between the Company and the Secondary Indemnitors, the Company is primarily responsible for amounts required to be indemnified or advanced under the Company&#8217;s certificate of incorporation or bylaws, any insurance policy or this Agreement and any obligation of the Secondary Indemnitors to provide indemnification or advancement for the same amounts is secondary to those Company obligations. The Company waives any right of contribution or subrogation against the Secondary Indemnitors with respect to the liabilities for which the Company is primarily responsible under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of any payment by the Secondary Indemnitors of amounts otherwise required to be indemnified or advanced by the Company under the Company&#8217;s certificate of incorporation or bylaws or this Agreement, the Secondary Indemnitors shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee for indemnification or advancement of expenses under the Company&#8217;s certificate of incorporation or bylaws or this Agreement or, to the extent such subrogation is unavailable and contribution is found to be the applicable remedy, shall have a right of contribution with respect to the amounts paid. The Secondary Indemnitors are express third-party beneficiaries of the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">No Duplication of Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Insurance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, trustees, general partners, managing members, officers, employees, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered by such policy or policies to the same extent as the most favorably-insured persons under such policy or policies in a comparable position. For clarity, an Indemnitee&#8217;s rights to indemnification hereunder are not limited by virtue of the fact that the Company maintains a liability insurance policy or policies for the benefit of Indemnitee.  Upon request of Indemnitee, the Company shall also promptly provide to Indemnitee&#58; (i) copies of all of the Company&#8217;s potentially applicable directors&#8217; and officers&#8217; liability insurance policies, (ii) copies of such notices delivered to the applicable insurers and (iii) copies of all subsequent communications and correspondence between the Company and such insurers regarding the Proceeding. Indemnitee agrees to reasonably assist the Company&#8217;s efforts to cause the insurers to pay such amounts and will comply with the terms of such policies, including selection of approved panel counsel if required.  Any costs or expenses (including attorneys&#8217; fees and disbursements) reasonably incurred by Indemnitee in so cooperating with the Company&#8217;s efforts to cause the insurers to pay such amounts under insurance shall be borne by the Company.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Subrogation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Services to the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation or is removed from such position. Indemnitee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.  Indemnitee may be discharged as provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the Company&#8217;s board of directors or, with respect to service as a director or officer of the Company, the Company&#8217;s certificate of incorporation or bylaws or the DGCL. No such document shall be subject to any oral modification thereof. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Duration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement shall continue until and terminate upon the later of (a)&#160;ten years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other Enterprise, as applicable&#59; or (b)&#160;one year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Agreement relating thereto.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Successors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement shall be binding upon the Company and its successors and assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and&#47;or assets of the Company, and shall inure to the benefit of Indemnitee and Indemnitee&#8217;s heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company&#8217;s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (i)&#160;the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law&#59; (ii)&#160;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (iii)&#160;to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Enforcement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve or continue to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that this Agreement is a supplement to and in furtherance of the indemnification provided in the Company&#8217;s certificate of incorporation and bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Modification and Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No supplement, modification or amendment to this Agreement shall be binding unless executed in writing by the parties hereto. No amendment, alteration or repeal of this Agreement or any change in law shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal or change in law. No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor, unless otherwise expressly stated, shall any waiver constitute a continuing waiver. Unless otherwise expressly stated, no supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement, modification or amendment. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">if to Indemnitee, to Indemnitee&#8217;s address, facsimile number or electronic mail address as shown on the signature page of this Agreement or in the Company&#8217;s records, as may be updated in accordance with the provisions hereof&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">if to the Company, to the attention of the Chief Financial Officer of the Company and a copy to the General Counsel of the Company at 15 W. Scenic Point Dr., Suite 100, Draper, UT 84020, or at such other current address as the Company shall have designated in writing to the Indemnitee, with a copy (which shall not constitute notice) to Matthew Haddad, Willkie Farr &#38; Gallagher LLP, 787 Seventh Ave., New York, NY 10019.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i)&#160;if delivered by hand, messenger or courier service, when delivered (or if sent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">via</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), (ii)&#160;if sent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">via</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii)&#160;if sent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">via</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> facsimile, upon confirmation of facsimile transfer or, if sent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">via</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> electronic mail, when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#8217;s next business day.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Applicable Law and Consent to Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i)&#160;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (ii)&#160;consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-14-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">arising out of or in connection with this Agreement, (iii)&#160;appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, Registered Agent Solutions, Inc., Wilmington, Delaware as its agent in the State of Delaware as such party&#8217;s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv)&#160;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v)&#160;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Monetary Damages Insufficient&#47;Specific Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company and Indemnitee agree that a monetary remedy for breach of this Agreement may be inadequate, impracticable and difficult to prove, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and&#47;or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and&#47;or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he or she may be entitled. The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertakings in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or undertaking.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Counterparts may also be delivered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">via</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Captions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-15-</font></div></div></div><div id="i057e64705caa436ebd203960a62cdb8d_4"></div><hr style="page-break-after:always"><div style="min-height:93.6pt;width:100%"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The parties are signing this Indemnification Agreement as of the date stated in the introductory sentence.</font></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMPANY</font></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEALTHEQUITY, INC.</font></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; Delano Ladd</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">(Signature)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Delano Ladd</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">(Print name)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">EVP and General Counsel</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">(Title)</font></td></tr></table></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INDEMNITEE</font></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:243pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#47;s&#47; Scott R. Cutler</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">(Signature)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Scott R. Cutler</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">(Print name)</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-top:12pt;text-align:center;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>esp-tsavf.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id496bba83e4c4d4d9d429686467d79f0_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HealthEquity, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15 W. Scenic Pointe Drive</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Draper, Utah 84020</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">November 11, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BY ELECTRONIC DELIVERY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Jon Kessler</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Re&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transition and Separation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Jon,</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This letter agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) sets forth our collective understanding with respect to your continued employment with HealthEquity, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from and after the date hereof and the transition of your duties to a new Chief Executive Officer, effective as of January&#160;6, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Transition Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Reference is made to that certain (i)&#160;Employment Agreement, by and between you and the Company, dated as of June&#160;10, 2014, as amended April&#160;1, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (ii)&#160;Confidentiality, Non-Interference, and Invention Assignment Agreement, executed by you on June&#160;10, 2014 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restrictive Covenant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The parties acknowledge and agree the Employment Agreement and the Restrictive Covenant Agreement are separate contracts and shall not be interpreted as multiple parts of the same contract. </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Transition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Between the date hereof through the Transition Date, unless your employment is terminated by you or the Company in accordance with the terms of the Employment Agreement, you will continue to serve as a member of the board of directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and as President and Chief Executive Officer of the Company.  Effective as of the Transition Date, you will resign as President and Chief Executive Officer of the Company and continue as a Special Advisor to the Company, reporting to the Board, and as a member of the Board through April&#160;30, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Between the date hereof and the Transition Date (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Transition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), you agree to perform your duties on a full-time basis from either your home office or the Company&#8217;s offices in Draper, Utah as necessary.  Following the Transition Date, and while serving as a Special Advisor, you will be expected to devote all of your business time to the Company.  Further, during the Transition Period and while employed as a Special Advisor, you agree to cooperate with members of management, your direct reports and other employees of the Company, its direct and indirect subsidiary companies and affiliates (collectively, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to facilitate an orderly transition to a new Chief Executive Officer, provide information, answer questions and provide guidance as reasonably requested by the new Chief Executive Officer, the Board, and senior leadership relating to any matter on which you will have worked on or of which you have knowledge.  In addition, you shall be responsible for completing all end of year assessments for your current direct reports&#8217; Fiscal Year 2025 performance reviews.    </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You hereby acknowledge and agree that the appointment of a new Chief Executive Officer of the Company on the Transition Date, or the resulting change in your duties or responsibilities, shall not serve as a basis for you to resign for &#8220;good reason&#8221; under your Employment Agreement or any other arrangement with the Company (including any equity award agreement).  Accordingly, by signing this Agreement, you are agreeing that you are not entitled to any severance or other benefits under your Employment Agreement or any other arrangement (including, without limitation, any equity award agreement) in connection with such appointment.  The foregoing relates only to the transition contemplated hereunder and does not alter, amend or waive any other provision or right that you may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">have, or relate to any other or future events or changes in facts or circumstances, under your Employment Agreement, any other arrangement or any other benefit to which you may be entitled.  Further, effective as of the Transition Date, you hereby acknowledge and agree that your Employment Agreement shall be deemed terminated and, following such date, your employment as a Special Advisor to the Company shall be at will, which means that either you or the Company may terminate your employment with or without cause or notice, and that upon any subsequent termination of your employment from the Special Advisor position with or without cause (including at the Separation Date), no further payments by the Company to you will be due other than accrued but unpaid base salary through the date of your termination, any other accrued benefits to which you may be entitled pursuant to the terms of the Company&#8217;s benefit plans in which you participate at the time of such termination, reimbursement for any reasonable business expenses incurred in accordance with the Company&#8217;s expense reimbursement policy prior to the date of such termination and timely submitted to the Company and, subject to your execution and non-revocation of the Release, the Consideration (each, as defined below).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  During the Transition Period and the period during which you serve as a Special Advisor, you will continue to be paid your current salary (at an annual rate of $750,000), payable in accordance with the Company&#8217;s regular payroll practices, and remain eligible for a target annual incentive bonus equal to 100% of your base salary in accordance with the terms of the Company&#8217;s Executive Bonus Plan, with the actual bonus payable being based upon the level of achievement of company and individual performance objectives for such fiscal year, as determined by the Company.  In addition, while employed by the Company during the Transition Period and thereafter, you will continue to participate in all employee benefit plans sponsored by or through any member of the Company Group in which you are eligible to participate as of the date hereof (as such plans may be amended, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in accordance with the terms and conditions of such Benefit Plans.  For the avoidance of doubt, you hereby acknowledge and agree that you are not expected to receive any additional equity-based incentive awards after the date hereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Treatment of Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For so long as you are continuously providing services to the Company in any capacity, each of the options and performance based restricted stock unit (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">PRSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) awards granted to you pursuant to the Company&#8217;s 2014 Equity Incentive Plan (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2014 Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2024 Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, together with the 2014 Equity Plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)) will remain outstanding in accordance with their terms, including, for purposes of any unvested PRSUs, eligible to vest and&#47;or settle based on actual achievement of the applicable performance metrics.  Except as provided in paragraph&#160;4 below, on the date that you are no longer providing services to the Company in any capacity, (A)&#160;any outstanding PRSUs that have not settled as of such date will be forfeited and (B)&#160;your vested options will remain exercisable for the period set forth in the applicable stock option agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Termination Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Upon a termination of your Continuous Service (as defined in the 2024 Equity Plan) other than for Cause (as defined in your Employment Agreement) following the Transition Date, and subject to your (A)&#160;remaining employed with the Company through the Transition Date, (B) execution and non-revocation of the release of claims attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) within 21 days following such termination, and (C)&#160;continued compliance with this Agreement and the Restrictive Covenant Agreement, the Company will provide you with the following benefits (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Subject to Sections&#160;9(c) and 9(d) of the Company&#8217;s 2024 Plan, your termination will constitute a &#8220;qualifying retirement&#8221; and the outstanding PRSUs granted to you in 2024 pursuant to the 2024 Equity Plan will remain outstanding and eligible to satisfy the applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">performance based vesting conditions as though you had remained in continuous service with the Company through the certification date for such PRSUs&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Subject to the achievement of the applicable performance conditions for the applicable fiscal year, (x)&#160;if your employment terminates after the Transition Date and prior to January&#160;31, 2025, any bonus for the fiscal year ending January&#160;31, 2025 will be pro-rated based on the number of days in such fiscal year that you were employed and such amount (if any) will be paid at the same time it would otherwise be paid to you had no termination occurred, but in no event later than April&#160;15, 2025 and (y)&#160;if you remain employed after January&#160;31, 2025, any bonus for the fiscal year ending January&#160;31, 2026 will be pro-rated based on the number of days in such fiscal year that you serve as a Special Advisor and such amount (if any) will be paid at the same time it would otherwise be paid to you had no termination occurred, but in no event later than April&#160;15, 2026.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, any termination of your employment to occur prior to the Transition Date shall be governed by the terms and conditions set forth in your Employment Agreement, as modified by paragraph 1 above, and the terms of any agreements evidencing your outstanding equity awards under the Equity Plans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Affirmation of Restrictive Covenant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You hereby acknowledge and agree that the execution of this Agreement does not supersede, modify, alter, or amend the Restrictive Covenant Agreement.  You further hereby acknowledge that your continued compliance with obligations set forth in your Restrictive Covenant Agreement (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is a condition of your receiving the Consideration described in paragraph&#160;4 and upon any breach of the Restrictive Covenants, the Company shall be entitled to an immediate refund of any Consideration described in Section 4(b) above already received by you.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amounts provided hereunder are subject to withholding for all applicable taxes, including but not limited to income, employment, and social insurance taxes, as shall be required by law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  EXCEPT WHERE PREEMPTED BY FEDERAL LAW, THE VALIDITY, INTERPRETATION, CONSTRUCTION, AND PERFORMANCE OF THIS AGREEMENT IS GOVERNED BY AND IS TO BE CONSTRUED UNDER THE LAWS OF THE STATE OF CALIFORNIA APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES.  </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise expressly provided or referenced herein, this Agreement and the Release, which the parties acknowledge and agree are separate contracts and are not to be construed as multiple parts of the same contract, constitute the entire agreement, respectively, between you and the Company with respect to the subject matter hereof and supersede any and all prior agreements or understandings between you and the Company with respect to the subject matter hereof, whether written or oral. For the avoidance of doubt, this Agreement and the Release supplement, and do not modify or supersede, the Restrictive Covenant Agreement or the Employment Agreement, which the parties acknowledge and agree remain in full force and effect as separate contracts. This Agreement will bind the heirs, personal representatives, successors and permitted assigns of both you and the Company, and will inure to the benefit of each of you and the Company and their respective heirs, successors and permitted assigns.  This Agreement may be amended or modified only by a written instrument executed by you and the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The section or paragraph headings or titles herein are for convenience of reference only and shall not be deemed a part of this Agreement.  The parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions of this Agreement and has had the opportunity to contribute to its revision.  Accordingly, the rule of construction to the effect that ambiguities are resolved against the drafting party, shall not be employed in the interpretation of this Agreement.  Rather, the terms of this Agreement shall be construed in a reasonable manner to effect the intentions of both parties hereto and not in favor or against either party.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Payments and&#47;or benefits under this Agreement are intended to be exempt from, or comply with, Section&#160;409A of the Internal Revenue Code of 1986, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and this Agreement will be interpreted to achieve this result.  For purposes of this Agreement, each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section&#160;409A.  In no event shall the Company or any of its affiliates be liable for any additional tax, interest, or penalties that may be imposed on you as a result of Section&#160;409A or any damages for failing to comply with Section&#160;409A (other than for withholding obligations or other obligations applicable to employers, if any, under Section&#160;409A).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding any provision in this Agreement to the contrary, any payment and the delivery of any shares otherwise required to be made hereunder to you at any date as a result of the termination of your employment shall be delayed for such period of time as may be necessary to meet the requirements of Section&#160;409A(a)(2)(B)(i) of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  On the first business day following the expiration of the Delay Period, you shall be paid and&#47;or issued, in a single lump sum, an amount equal to the aggregate amount of all payments and&#47;or shares delayed pursuant to the preceding sentence, and any remaining payments and&#47;or share issuances not so delayed shall continue to be paid and&#47;or delivered pursuant to the payment schedule set forth herein.  </font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument, and electronically delivered copies of executed counterparts shall be deemed to be originals for all purposes.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="id496bba83e4c4d4d9d429686467d79f0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth below.</font></div><div style="margin-bottom:30pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEALTHEQUITY, INC.</font></div><div style="margin-bottom:36pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Delano Ladd&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; Delano Ladd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;  EVP and General Counsel<br>&#160;&#160;&#160;&#160;Dated&#58; November 11, 2024</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agreed and accepted&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jon Kessler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Jon Kessler</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>Dated&#58; November 11, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>goldengateprvf.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idbba870cdda14310bb7e1963de5f2ae5_1"></div><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:151%">HealthEquity Announces Retirement of CEO Jon Kessler&#59; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:151%">Scott Cutler Appointed Successor  </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Draper, Utah &#8211; (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">GLOBE NEWSWIRE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">) November 12, 2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> &#8211; HealthEquity, Inc. (NASDAQ&#58; HQY) (&#8220;HealthEquity&#8221; or the &#8220;Company&#8221;), the nation&#8217;s largest health savings account (&#8220;HSA&#34;) custodian, today announced that after leading the company for more than 15 years, Jon Kessler, President and Chief Executive Officer, has decided to retire effective January 6, 2025.  Mr. Kessler will remain a director and act a special advisor to the Company through April 30, 2025. To succeed Mr. Kessler, the Company announced the appointment of Scott Cutler, who will join HealthEquity as President and CEO and as a director effective January 6, 2025.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">HealthEquity management will host a conference call for investors on Tuesday, November 12, 2024, at 4&#58;30 p.m. Eastern Time during which management will discuss the transition and succession plan.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;HealthEquity&#8217;s strengths and the Board&#8217;s thorough planning enabled me to make this decision now,&#8221; said Kessler. &#8220;Team purple is the acknowledged HSA market leader with a deep bench of talent, full pipeline of innovation, and the financial resources to realize its vision of HSAs being as widespread as retirement accounts by 2030.  I expect to marvel at the team&#8217;s future accomplishments just as I have over the last fifteen years, while investing more time in my family, including my new granddaughter.&#8221; </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;I could not have asked for a better partner to lead our company,&#8221; said Steve Neeleman, Vice Chair and Founder of HealthEquity. &#8220;We wish Jon and his family health and happiness in their adventures together.&#8221;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Commenting on the succession, Robert Selander, Chairman of the board of directors said, &#8220;After an extensive and rigorous nationwide search process, we are thrilled to introduce Scott Cutler as our next CEO.  Scott brings to HealthEquity a strong background in digitally driven growth and a long record of success leading high-performance teams. We believe he is exceptionally qualified to build on the Company&#8217;s established strategy and proven strengths.&#8221;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Scott Cutler, age 55, has served as Chief Executive Officer of StockX LLC since June 2019. Prior to that, Mr. Cutler was the Senior Vice President, Americas at eBay Inc. from August 2017 to March 2019, President of StubHub, Inc. from April 2015 to August 2017, and an Executive Vice President of NYSE Euronext, Inc. from April 2006 to March 2015. Prior to joining NYSE Euronext, Mr. Cutler was a technology investment banker and corporate securities lawyer. Mr. Cutler serves on the board of directors of Brookfield Renewable Partners L.P. (NYSE&#58; BEP) and non-profit Vibrant Emotional Health, the force behind the 988 Suicide and Crisis Lifeline. Mr. Cutler holds a B.S. in economics from Brigham Young University, and a J.D. from the University of California, Hastings College of the Law.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">HealthEquity CEO Retirement Succession Conference Call</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;November 12, 2024</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Time&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4&#58;30 p.m. Eastern Time &#47; 2&#58;30 p.m. Mountain Time</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dial-In&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1-844-481-2556 (US and Canada) 1-412-317-0560 (International)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Conference ID&#58;&#160;&#160;&#160;&#160;HealthEquity</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Webcast&#58;&#160;&#160;&#160;&#160;ir.healthequity.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A replay of the conference call will be made available on the Company&#8217;s website at ir.healthequity.com.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">About HealthEquity</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 16 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to our mission of saving and improving lives by empowering healthcare consumers. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our &#8220;Purple&#8221; service and approach at www.healthequity.com.&#160;<br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Forward-looking statements</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;seeks,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;should,&#8221; &#8220;assumes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;future&#8221; and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">risks relating to our upcoming CEO transition&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the significant competition we face and may face in the future, including from those with greater resources than us&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our reliance on the availability and performance of our technology and communications systems&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our reliance on partners and third-party vendors for distribution and important services&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to develop and implement updated features for our technology platforms and communications systems&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our reliance on our management team and key team members.</font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January&#160;31, 2024 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Investor Relations Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Richard Putnam</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">801-727-1000</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">rputnam&#64;healthequity.com</font></div><div><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>hqy-20241111.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09a9bdbb-3152-4f48-a046-792b871de3a5,g:43c4cb01-b918-4d87-8edb-365c83be4dc1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hqy="http://healthequity.com/20241111" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://healthequity.com/20241111">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hqy-20241111_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hqy-20241111_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://healthequity.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>hqy-20241111_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09a9bdbb-3152-4f48-a046-792b871de3a5,g:43c4cb01-b918-4d87-8edb-365c83be4dc1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ddd0ebba-1b2b-4920-b4ba-8d25e4121107_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e8ccbe5d-1b3f-491a-aff5-0adc98ee5999_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_17a55a80-0d78-430c-956b-21d4e3aaaa6f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3697f07c-7a08-40e8-911b-fd087d5576b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_30da7c44-fbb3-4986-af57-3b7e75cc6b49_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_883c7bc7-f092-4824-86c5-a6b0bfd9fa97_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7d20aaea-6dd7-478e-bef8-2160ee95a135_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7e301b9e-cd8b-4fba-93ba-1dc37bd73e26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_dff5dd45-bc0e-44e1-9dba-4b0402a5f93a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_388b725d-a532-402a-9767-b1d12124ce25_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_64e32d48-f0b7-45f7-a4d3-17e2de28ade0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8c6be8e7-f08a-437c-90aa-94ff4989c3f6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9469d168-2e93-4230-b1a1-70dcd2592560_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6e9ae00b-1763-4196-b220-331edb36015a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ce7ebbb7-363f-4ec2-b2a5-fb89ca7cea94_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f7354ded-6c35-465e-af05-f81fc4d1d687_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_63f40228-90a1-4876-9890-a26506b95567_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_67ae72af-b261-421d-8464-3dfac2627983_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ed836221-bc43-4140-91bd-0dc8a162e6b8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_256ad6e4-9647-4fa8-827c-a8a25583a714_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d98cef74-89db-49ee-9d17-f37170cbcc6f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2a67fb67-1fd3-42df-87f2-c2b0d6e6e645_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_42d75464-1d67-493b-8604-378cb9819aa0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4577fb20-f8f8-4c4a-8dea-30eca7051f0d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>hqy-20241111_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:09a9bdbb-3152-4f48-a046-792b871de3a5,g:43c4cb01-b918-4d87-8edb-365c83be4dc1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://healthequity.com/role/CoverPage" xlink:type="simple" xlink:href="hqy-20241111.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://healthequity.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e6e42c7e-4377-4954-b326-639dec4f20b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_DocumentType_e6e42c7e-4377-4954-b326-639dec4f20b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_eae78f83-0aa7-416f-aeab-d56d1ef967d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_DocumentPeriodEndDate_eae78f83-0aa7-416f-aeab-d56d1ef967d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_78011b0a-9070-4dc8-b440-c77400d1e5b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityFileNumber_78011b0a-9070-4dc8-b440-c77400d1e5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_50cf8737-7ebb-45f3-8423-6f22d7c84e64" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityRegistrantName_50cf8737-7ebb-45f3-8423-6f22d7c84e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_aef5a0d9-027d-4889-8f41-49c3906568e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_aef5a0d9-027d-4889-8f41-49c3906568e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6ab96b0f-7efb-4c9d-8b51-a7db0907801c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityTaxIdentificationNumber_6ab96b0f-7efb-4c9d-8b51-a7db0907801c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c3bc0c66-79de-4c67-9c57-9231cbc2ec69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityAddressAddressLine1_c3bc0c66-79de-4c67-9c57-9231cbc2ec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_09258723-bbb0-44be-8c62-a75811531848" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityAddressAddressLine2_09258723-bbb0-44be-8c62-a75811531848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_27cb5529-dea9-4101-8c53-cd0ede5c8395" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityAddressCityOrTown_27cb5529-dea9-4101-8c53-cd0ede5c8395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e9e58762-e636-4cf5-bd57-66b243c2d47f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityAddressStateOrProvince_e9e58762-e636-4cf5-bd57-66b243c2d47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d325d35d-c27a-4204-8e87-49631a99ceea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityAddressPostalZipCode_d325d35d-c27a-4204-8e87-49631a99ceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c202a0f5-f53a-4a76-a2c6-5e766822d74f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_CityAreaCode_c202a0f5-f53a-4a76-a2c6-5e766822d74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_636364da-41d0-4695-91cf-1ac6cfda1fb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_LocalPhoneNumber_636364da-41d0-4695-91cf-1ac6cfda1fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3abe700d-66bc-441c-a4a7-ae8afa6527a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_WrittenCommunications_3abe700d-66bc-441c-a4a7-ae8afa6527a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9790b976-612d-4d07-ac46-34d242c40c6a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_SolicitingMaterial_9790b976-612d-4d07-ac46-34d242c40c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_33b66cc9-7db5-4d1d-84ea-758c4f00d216" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_PreCommencementTenderOffer_33b66cc9-7db5-4d1d-84ea-758c4f00d216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2895ef40-cdb1-4435-a39a-90c2959c6702" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2895ef40-cdb1-4435-a39a-90c2959c6702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_57ed290c-8d45-41fb-b5f0-ad43aea4ac09" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_Security12bTitle_57ed290c-8d45-41fb-b5f0-ad43aea4ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d94c1ab2-8825-4405-87d3-44f72fb99134" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_TradingSymbol_d94c1ab2-8825-4405-87d3-44f72fb99134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a6e9771c-daa4-4037-8a59-8708ccdcbb22" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_SecurityExchangeName_a6e9771c-daa4-4037-8a59-8708ccdcbb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_776395b5-e6dc-4ddf-a338-3e940fb4149d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityEmergingGrowthCompany_776395b5-e6dc-4ddf-a338-3e940fb4149d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_27469d03-d953-43ce-93a8-898255649f49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_EntityCentralIndexKey_27469d03-d953-43ce-93a8-898255649f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_77132527-b8b0-4fbb-b27a-d1b532ed6ed8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_334cc38c-7531-41be-a798-f3176256db5d" xlink:to="loc_dei_AmendmentFlag_77132527-b8b0-4fbb-b27a-d1b532ed6ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !14   #4" 8    "],3%    "7!(67,  $SE
M  !,Y0%USO"5   :!4E$051XVNS8@0G"4! %P11D0[9CX]K#@V"2G8%KP"/_
M<(\O    \ COU^>O W0<'I+N40# _7 W[-9<:P#N?B. #E$Q?!0 Q"A[M$>[
M-:(BX$9XQX"%J!@^"@!BE#W:H]T:41%P([QCP$)4#!\% #'*'NW1;HVH"+@1
MWC%@(2J&CP* &&6/]FBW1E0$W CO&+ 0%<-' 4",LD=[M%LC*@)NA'<,6(B*
MX:, ($;9HSW:K1$5 3?".P8L1,7P40 0H^S1'NW6B(J &^$= Q:B8O@H (A1
M]FB/=FM$1<"-\(X!"U$Q?!0 Q"A[M$>[-:(BX$8\\1WS&\#Y1,7P40 0H^S1
M'NW6B(J &R$J>LMA(2J&CP* &&6/]FBW1E0$W A1T5L."U$Q?!0 BC&J](ZZ
M&[Y1(RH";H2HZ"T'4=%1L"- C!(5[1%1450$$!5%11 5$14!,4I4M$=$1>,[
M T1%41%$11^1J AX=T1%>T14-+XS0%04%4%4]!&)BH!W1U04%=T-?QB-/Z*
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M5(2*4+%_3JA\E^+H,Q5]_%G!YULK S>[Q,2;$J]0L<ZU*8KV+*02\K*#@>;
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M7R< H/<NUC;L C@C]-P40D4T+HVFHEX 0.==;-NP"^!,T&]3"!4!  "&#+H
M>JU^FT*H"   ,&30!=!K]=H40D4   "#+H!>RQ&A(@  @$$70*_EB% 1  #
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M'!4!  !"1C7 :O]TM(^C(@  0,BH!ECMGX[V<50$   (&=4 J_W3T#Z.B@
M "&C&F"U?QK:QU$1   @9%0#K/9//_LX*@(  (2,:H#5_NEG'T=%  " D%$-
ML-H_[>SCJ @  ! RJ@%6^Z>=?1P5 0  0D8UP&K_=+./HR(  $#(J 98[9]F
M]G%4!   "!G5 *O]T\P^CHH  ,=N    ___MV$$-PT 40\$ *J'0*?$MAIQB
MUS/2$MC#D[[/ ?[7_?F^]@!6^Z>7?2Y?    D'%4 ZSV3R_[&!4!  !"CFJ
MU?YI91^C(@  0,A1#;#:/YWL8U0$   (.:H!5ONGCWV,B@   "%'-<!J_[2Q
MCU$1   @Y*@&6.V?)O8Q*@(  (0<U0"K_=/"/D9%  " D*,:8+%_=#(J @
B & PY!&C(@    #PR _'U5F/G)755@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46116339781536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 11,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HEALTHEQUITY, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2383166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15 West Scenic Pointe Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Draper<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HQY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001428336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V
M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= 9.
MMO8(72A]95,. 46=W=3%<]0!;\K!XVBLA H#E&^J%977DHHM)]W1ZTSO'R:/
M6D;KW$JY]_!*MAQSCG^T_ %02P,$%     @ 1X!L620>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ 1X!L60=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " !'@&Q9=PGO1NX    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( $> ;%D9117U-P$  "<"   /
M  "  6X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !'@&Q9)!Z;HJT
M  #X 0  &@              @ '2$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !'@&Q999!YDAD!  #/ P  $P
M@ &W$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   !%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hqy-20241111.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://healthequity.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="hqy-20241111.htm">hqy-20241111.htm</File>
    <File>hqy-20241111.xsd</File>
    <File>hqy-20241111_lab.xml</File>
    <File>hqy-20241111_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hqy-20241111.htm": {
   "nsprefix": "hqy",
   "nsuri": "http://healthequity.com/20241111",
   "dts": {
    "inline": {
     "local": [
      "hqy-20241111.htm"
     ]
    },
    "schema": {
     "local": [
      "hqy-20241111.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hqy-20241111_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hqy-20241111_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://healthequity.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hqy-20241111.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hqy-20241111.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://healthequity.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001428336-24-000104-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001428336-24-000104-xbrl.zip
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MBAT9GW)&>8PVOBQMQ?:5X%>4FN<^22?HF3P&QP0F@JX/(O50%(A>!QYH!L,
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M>[$M53FR\L1+@WJO'ODI8,^'Z!;,I]U9]I:THLL ![A_$G_* 5\D& L7]W8
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M!.[R:U%Z[+0S@!.?2:TQ+<HPU\0PP85 ,ZTYUB+#9X.R+S( &[%UL+WUFFC
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M_5S1 *6>9\IP;_5\C8]G)?<M8;:\UU@R7^0I1J9&9)&HI<@6#693@\]UA![
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MRH:<@>=>MY&9L\@L]]^-MF;$=WA\*9MW%9AU:($-H<T#C0(NRB(?5#(X4)*
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MZZ!KO6L_NV,&]$"[RI[='Q_XCCBP<I"G:*".@N3@EIM'X\/[?:QY9(C$A8H
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MP.;EGZ23"+YSE5>%\E)X7H5K(%FL2 )#CY<M#<RC*;<4JJ6.3BJT^W7?WH7
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MC*;!=# NBD$31%9#O3K]>+*-85R2=4#66&H(+@VXU $68VYB*G535_9HD[;
M'TS;$X<F8]8; K2 0D.15^0<_:,'8*^1'J:]UY?-0&/ K5A54^;#H:PI4F+F
MQNQQEJ9 ON=2:ROQ10;WN?;LX.%B$]..1L+N\[#C\X88OG24K$KBHN'*1=/N
MY07C8F?@J.%ZU;*V'MB1C>^&5PSTNL[(+V- K3PN5,+PM.<+."=390/ZYL-^
M+7!7MO@Z9V]-W<%MNLDB;QUVT73E^-T[T&8S-\^%; ;?-=BXP'<@G]L.\GEP
M!_+9)UO 1TBHU+? A1@D2G3,+,&"K7619J^ZV@23X<UTJ9O&2*:(I'_C0N#/
MJ?KTK?1?:Y#R;WI"T1<X Y<M(HJM=,$6H:UT7]GX= J%VC&'+5LX6#$EAT80
M!ZS^O"''NIUR6C&J%H2,W5LEZ]"2K\7/=ZUI#-B?)C-C(&;&QKWW#-/96LC6
M-J_D4;Z2[:-LG[ X_"X3,-SOBIQT^.)*EYUMK+1Y5CNJJ*/@W:E7/H7'!$LY
M"JU,?UED:F4^ NX=:]7MYF$8M7GM<)Q'ZWU%$8E%C>P5?!E@9V'^N9R#;G&H
M-O((.==^JDK=8LG#2[50"!I&6E6,0[,7\^#QL[<43 )?RP-W[Y?(?XN!Z1N,
MR<+,37IQH8S95']D$BIYJ3+]1P?7.:5#BL=_:GGCLQR7!CO^2D<*N5L"EO)?
M3Y='WH;/YEI.'SE18[B.^4JQ ?I)\IQ,<]@CTV:E!POTGMZC.3&\:OWP+A9X
MZ/<L.'X'*YN"NV"A8=[!J^=LS!9+A1>)8$X8.>,?5YLK9*3H"=-:)&F9M":C
M T07NC>SY$B"R32!3+:'OT5HL_[GI8<8M6\&>8$R"^<7*8\S(R>!O*D^S:]U
M"U?(-,94G[96$3I<0:TM:XTU.9:22]Z <?N)7UXCW=SX;;91ZUPJ!BV7C9;>
MK%OO0.0PQMAZS;,<""-V"A@-V%L/OY*[U0N$_- MP[IFGA-5/H#-L,0O(,%$
MO;:/,<2KF*U7)5L,]B_NO.%.!^<-$_"D?,!7;%SJ@]+\K<)U[9L)!/##YYU<
MTY9)]!@X(EJL#X,2POZT^$*N3[)O,AOBT <!7L:R]<!6#(LTQ OVVLLP'R(_
MRY*EQ]Y[J)IQA&R)F%Q%?A60P>/B83"RP,,;8B8'#LJBHB:U;MQ2]&=Y638D
M!ATX3CK%HKV77Q)!S 1%/],!2&>BZI()"(8PN]+18I&)[57W1N9 W-3^1$C#
M^HE%%T1WJ F!)X]SEOZ9">;HIG47^=\2^?>KHY?9S(3(O$^Y@\"4UP$U]*\G
M;T]L$.[B[:L?7H--1<+T_!0A#^-:>WURN5<[&E3MU=4),K/AHI[ >AX[K4I9
MJT7.7!<+N H5WT^)6)I3CA6Y[FSWZZSAGA$ZA%.:G41[R=$NUM[WJ!9 RNT3
MUR86#8[^+3Y)DI\Q5HNWD+MD^X.!>3BN/';831R ^ASV*O>Q+QQ[I278I8W(
M!;#KL5HSXQ[$.=/"<]P%8R.V("*@+SA,O7Q_A"1U+]22>_7MO<!XKA65>7E%
M_F!SJ^4\!K7!\ @<1##DI'6R#7K@>2H+GQ4A+'EA,@*C?NB@1U&#Z"%*1?S<
M%LU[AG U^ZA6-%.JBMX7PF]<(KL'WIQ515%=[;7'Z/%==N:V9V<>;LG.X#+G
MV3^^R4\?/M:/'CP^?3A5ZL']1WJ2G9_>__;1J7IT/LTF3[+_?O#-IV=TOKV_
M_XS.+="*[[S0'(IUE H<F\HMQ[NM8/$T@%441$#*%3XF])"7+9D=1(B&F5Y=
M[D J9A<K5)4/[N\G_17OR_SBYY]^>?[Z/P<QEW]?//_QW;\O_N^OK][])TU>
MO7[Q^;>HI3BH%<<82+N'';C5LM%/S3^>97FS+-3Z:5[2(.E+ST);$ZRE9RLL
M8IFJ0MY"+^0_RRU_>'IRRA>]A1O:9N;%(@-.Z$]_;[/AW[Y]<O+MZ>8_GYZ<
MV;_]G9[-SX<9-$M5_N.;^]\X,44K\_1\^2$YBQD?_6GP#/9P^Q^2$GGP^%E#
M_TN)K[)*?H0)V'.PPX1E5^EH+-&'0K\'1_[LQDL!S_ARZW #ZPA7YNBM,8^.
M;[(:MVO[[[8\V/)?:JPM*=7BD/?\XO_]0MY9K^[F;O^_/WJ'.:3(UO^=--)G
MUO81,_*6VA&O7K^\^.GUJW<7%U]D.E]FH>XLDW&+*=\R>3N%D21O3I(7'5S0
M^DY4_3FLD[MMOYF%LK.:^DRB=O=:ZKOG?N)SY6A^\5+U:T./IQQZ_/;L"\49
MSV]^,VA(5AXFOV PNZV2"]?ZRH:MOO"8KUNT^YMI+[YX@/N:V*7\[Z3*UO"?
M>;LHOO__4$L#!!0    ( $> ;%E1I^WXP18  .^"   -    97-P+71S879F
M+FAT;>U=;5<;.9;^OK]"F^SVP!Y#8T(@D$S.,> DS-# @-/9?-HC5\FV)N62
M1U4%>'_]WA>I2E780&?3[8+3<^9T-W:5="7=U^=>7;^;Y-/D_;N)DO'[?WOW
M[QL;XMA$Q52EN8BLDKF*19'I="R^Q"K[)C8VW%-'9C:W>CS)Q?;6]H[X8NPW
M?2WY^USGB7KOQWGW,__][F>:Y-W0Q//W[V)]+73\UQ<ZWMG?'0[EFU=J)]J)
M=^+]>&=[?_?-[L[N7KRW/]KZG^X+>!4>YW>R?)ZHO[Z8ZG1CHG#^@[WM6?[V
M1L?YY*"[M?6?+^K/23N&1X<FS\WTH(N/YNHVWY")'J<'M !X861@N>Z-R"3&
M'KS<HO^]Q6\V1G*JD_G!7P9ZJC)QIF[$I9G*]"^=3*;91J:L'O&#F?Y?!43
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MZR)3>29&QN8380HK8/Y$13F80$',G>7 S>C@W6AXPJIL!M^*W(@Y/YWF.BW
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MII!6@0DE7T^1.;0R H.*;V<3F20B-3G(M,#0TLZL<O([+9)<SQ*FCL09Y\I
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M?)%!\ ?'_@%"?W-#<K=((>#IWTQTHDBYXV.+I#E0'.#UJ%N$"\#HP!)C=6V
M6= G\A'K$'-':+%H@74]@ 05%M<)84]A%Y#%AQG0Q29/Q?<05FYX9 QL!'(O
MV3I6*:0-X8CEN+)MUEDJIY;8M3.T_VX^U31A':'A.?<:/@Y.&/^1%4/0H!KV
M&PC 9\DQI6!_I!,-Y&1BK8)@$ABJW;+EM?Q'T+ZS-L@5GNU(1K"9.1ZN3$$H
MT+N;AXC)PQ#)S)IK,'5P<BB6I*%1 K(;./9_%1 2P =\<O[)<:'9=P+FLTIF
M)I5#F-4J>IS]+N21>Z=M6+M,I1ID.E$2D;B)GL%PB?2F$?<=2$.4"-8$(A!-
M*N&;2!CWQMAO,#-B1&0NJV?HZS(> ED[ 64#KC(O%)_@Z 5D&#$_6*P>@H3!
M9A#C)HJ(P"=42N[<'#%DF64@S2@Z!"DZC+"P%GV&NA@YY20^Z"P"(?V*KY.Q
M=IJ0MM*J:ZUN,B!//)-@Z"ON/5A3!'N6Q*,R)S:0LQGF(\G;1MM['^,T?2Z3
M+E;ASC[ B6+X"0<8360Z1BZO&QY;'3H*$GS6":+9P+=W-HF/&GG2.8OXB=-7
M8P,ZF@7"R2@#RSSCPM ;7J95D)*5UB*-%;)<BQ5T&B4%X=/XIR*X6<@;] C+
M7 "Z-#V*;> Y5*FP^4@EFQ2@OQ',8$A/+_,#<![^4UP] CMYPB8-Y\S4-=B1
ME*TODSQ4J1JA"?CNA5;KZM"B39&+1$]1ISE-M'2Q>)C@;Z=H05 MX)9E!8A]
MP%"P(8B,P"FIL<%5DEHAEP,5I6DBS.B_H[&C^!'9EQ>&7!L;> WW128Y:C""
M'W%A-Y("C')YI"<SS;J(2T/*O9W*^7+Y#NLX9H8I.F ]>*V65G8X=;!5O2*'
MF4F*?/DK2_-Q[]\-[?M%11C\SXGU(\S <=@8 K-_VR#T_D F-W*>O?A!M2D/
MD?-$$G9H>SJL9)"CO" QF\#'HR(O0-C4-=D1M#BDI<A_'1&ZAI]I&Q53S$Y%
MJ)T>D+3.$CFK": 36Z2G,I3(FNC(.JD/O=)F&F5I&/VPPE^N(DHS'.,'<0CD
MP!@=D&'OM).0QW[2&@#TB+"[FDCFY$%TW"9,%:R(J:S"CB9ZA+M44G9G>M)!
MJ!*<)HMDD9&Z!+VA/69.,Q0S2I_/R5%&SPG>]N.&J:Y@< J(D);F^KS@+YD^
M-!UL<1O!.(1H*?B2?-IB)N?LUS@WSJ^<,Z%EP!,7RG$3K(<@-8O9T2%,6Z0S
MJ6,TF0CT)A@#A& >!=I^?<&::ZSKA_,&YCY6%;/"9@6BU5ZAAUA>,T;TS ]*
M/B5)J\8E #W2,_*G>:LH7H.1B.=JQ%JEIT.8F+EWY 2L=(A5%?-A;)AF)-;D
M(L;+,,@FJ>[%QE0S Q'+',R,KGC;[VF33&8X6$-"G 9VU<6H#>"J@]_^,TQX
M<^;&#Y&:= -\5!.5W,D9 W#8,]5QHZ6(F3F^6E,RFE":+H;=3NDH07S7EU?*
M/2GO=OLI0?UXSL!'L@5@__%#^ 9^,^,_'192B6?@CB_'8D)L?HA9)]!$M>C,
M::0UB8@%_#\M8!SKY.<_]EYO=6 70"6"'B0Q?J2L@H-9P,#XF@5+!>()!ER3
MR<9U637%S+@"9B[C2RERX'F5>R) /:!*N\;<05IDZ/?"I[ .=)DJ*"E0JX_)
M930)K6*J0YKE O1@IWH7J,99F0*_!T.*$'#FF"T7/IF WT((%TBZAO_V 5P4
MX.&(!UWK&$<,PUU#N@9HX)"*M-:(XV,,KYW>8#U6 0H57E:+X1N06,-L/8BH
MH;U1Y,0NX:+0*N"&(Q3@\+"&,:%(TE@F@AP'MGKD.-2@_!J:5#="&'Z5;-*8
MOG*_0K1Z#3ZF+60JG'5TY1%MQ]4.W0XB&V:MP-7N%2J7Y&'>RTJ36UL%(<SL
M-LIKX\ R3 2:8IC_!D>YBL0#<-FJ2/EXT\L B W'R!LLHI4BH9@Y6UQA]4Q,
M\:NG9(H'>)7$*TJN&10].J,5&V9DV,R(Q'"VPW.?TX.FR)*Y X I L.\2,0E
M>,W<.OPKDC,94=40>H%>99E9@"4'QH!YUKKJ$_C/+#?1-X@B0)[66JFS+BZO
M/K=#5SGY'H-E<_J!XIA&/-1T :CHRG'?2:DK4'>U/<,94H[TMN,0ZL6+P39O
MW[?-[4S4AT2W9(<Y0,T-N,J(#906N<D,'(>V<E<#*ENA.-9]Q0M%):;(R^KW
MQ=Z/9J0&@ID KT?7'53-S&2<&$;57Z37G 0D'=FI>;+X#9[E3R]W]MZBO5%Y
MGGC]CT #AQZ-<,*EB&"?*10)+<=4H<E ?ZM_&ZD9P7\N2TD8"Z)<H!IG$]9H
M.XQ!='S6B'RAAK-%%M"#^+_-UJWU7.TLP5C!EM)6\$24C>344D[0E:Q\R)AS
M] ROP1I'2COP4ZP=NJ$I G0[[.UI>)+J5ME(9]*'F$$X#3.ZVP\Z;6XJ6UP>
ML,JP/!,'<>=).8@!=G?A$TFK=@X_$UB]$)\^*AU$<<6"0N&H!_T<JS6-RGH(
M'2.?'C%277]S::Y@/4@&+*W@:0*:I7BRJ."[)69P)]UZ;_$I2..CX%'+\"AA
M(HG4&#WF.6@WEUK$;%#6TCM^_E)V;Y6<UV(OR2'?;3#EQ+P@+=M=L"#SK)DG
M:R18P)8<.3FHKK11H8L.#7Y8*_#("P*=F@"14?(50PRK.1&KZ"N3.W<+P=IY
MZK441QO.GJX)_T KW=UZLS(SO2;76V.G7VW2/EQ5)N2*JTPR%IW]M8C#OOVU
M>'T9T$Y&C^.29JJS!)GA"/("@5W/\ CYPZEPJ4JN+8E6$ <QDG+'N6P  *@.
M</8F$-"TPTNC )PI=-TQ>92-YDV_L8VE+'] EXK'-3;9_K.0YD?IAKMP(<9
M5-=78?$28RSRVKCNTR?=V)FLD$P?T=WO]>%=5CW2SJ.CV*Q,59',@>[=)Y%\
M+OIWV";]VVTJ8,Y-/A89"-C"A\'!D[54X]JM\X?TW9*;LM(G3*$T+X5P;;0K
MQJC=,'_%K5Y><V4+IU0].0$-6%F,O+SPW1(1 &=JP_*]-@^84)5UX?.*Y/T!
MIS>SJ17$<:-L>'> @B2LEYR:@DHQ"<)9KV;$W+FK@Z$+FU0, U'!C2D2=S7@
M1F>J?-99'Q2]U-3#Q8@K7SI4( 1$PO=4]B:P,,X%@N%%[M=N]>2QSFLG5&(=
MY4+H:'[TSN_^R)U?7KKP%(YA]]%(T':;K,9]25A2]_?7V\$VTG[5*ZV:TE]6
M$XXA(K)!M<+"?'$-A+NOB#,34Q.#_>'Q2B!3=(4<FNNRDC"H]:"$L!\A@V/%
M"XP1<C?-$WIW84&UK]VF:Z\!2OU,P+_73PG\ZXU&VMW!P1-M;]^!32$>?[^C
M@LK(9M>@A;*H/BO ?(-R!<XFQI]W?)T]JD@JM7\8@G!D^4K6!>15-<C+T0\S
M!$:6R^3U@2X)+<^?+J*^%0DIO+HO*TU9ZF,N=_% ;[W&-%999/5P2:X'.;&L
MLL8(JZI$6+@+=?RJ5.OU6S!"3Z<JQNN+0-FHX!MA^/P]E#GH0.R A\W:&U@;
MZ(GGOIC'MRIX)CIW]RGIW(&\5;^3!&P_**1+M>LJ1;)'?FB020WN06$/F"HF
M0W4Y,0GY%%30"B(3A%DY;FV0,2:G$Y4]7?!BD8(OS124?N5WN>R-(2=9IUG!
M=\[<8%CJ6-W7!'_%55LF\N:92,_>4Y*>C^3TXMF>RIL5>R3]_S[J7PS$ET_]
MR[ZXN.SW?[D8](_%X5?QH7_<O^R=BM/>EXX8?.J+7WNG)\<G@Z\=<7(VZ%_"
MPX/>X.3\K"..SL^N!I>?C_BOWMFQN.A??CB__*5W=M07YQ_@]9,KT?N(P_?/
M!@+^^'C^:__RC&?"%^"CP;DX[/NQX)O/9T  S0PD7/$P?7$%D]*81T .S'%V
MTA.]BXO3DZ/>X6D?!RGGN1*_]([[-#R/[:B"L4_.8+#>@$?KB"\G@T_GGP?B
MLO^Q=TE/ QD?8,P!SD337WX^[5]M/I>+QF^>DKST4\3T6^+$_S&3+W9$5VOB
MJG*A"CU1MS.+'8/GE>&CFYNNWQV;04U%9DNRH^XR%)?RYP\V9+NGH9HO_.8[
M+)0GHNMPC^NGU@DS2Q2!,=?)"E]P[4U=PO6>3HQWNJ'2;,X%<#T9@J8Y91@G
M_ T027E@!% "< +^JO5<S7X,";CWKD;0XDTW[@9A9;)Y;T'^_0>*:X+]KER3
MV-#9<)@J*"=0QJX/QZC^0NEBW.>QO.,@4+PG7, &@_,5\==\59?<I#NLA5T"
M:RMEA%&[]6*5'WA8N!:Z4F 5"@0\1TD[;(Q01-A#!SN9N1IN=Y]04N]'8D:P
M&9/%'3VI>PU."%&W+7O@^ LT\*J/T!:Q@/M;VX!S/<$/D44] &KKKM^0P1,I
MP3;J"X"@0<E"FH2/WFMVLVQ0N=P!_3,=^N+]PA]W>.+IT+;X0/M/R0<Z8G,6
MK;J(QO4&R1P\@\7,)<R.O]!"=@FU->(_F3/_9)JY.1"VOM7*F9+23V -<J<K
MJFMJ($FOWP5"'2U>Z?ORP.7 *BE+?'PN)M2'"?L'N:1>JL8FUY2PJB<BRLXD
MV0(H%A_ H3!MQ-=UL'T1WL*9<QLQL")Z6' ;"ZS:PCEQL&;3&2I]+!*N>PS.
MVJM\9Z)H&7(ZU.-"LZ6SU+#') B(R;%$Q<MUVA9T <:8M-Y.?6/++* K-2W;
MS\K%D#,VL);<UJ)Q5;:V&R7(4#E?>/CA_7Y@P%117JA<$4^?EG<#R1HV#Y7J
M17/N\7%-#DJY6M=W@M;Y3.",[E9[=-/VYO8#NJG$:K?V5UKZ"EQZX?MP!#<F
M&OV6FA)L'?_%C*U16T*0#VX=0ID4RG6P1]WQP+0#S&'%/IJ@/M_H EYB<KA
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M5\$YN W?Q?NM[][_\]#$<_C7))\F[_\/4$L#!!0    ( $> ;%G>JYY/M1
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M\EX$AIBG4F8S:[E=S0 1+L"49."*S#/>NLE1\7/DSP5=]*#(CN69XFS!6 8
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M69H-E4(#]AUR)QY$R6S&P\4A M+@GISX P<P*\*:FM$\Y 1>$ Z^;=)_AV.
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M^+IE3HS9SNFFHYSP&G2VZW5.=9W\.->)#G+]/QSALCN\=9QC6]L&R;5YZLS
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M$T=[_P%02P$"% ,4    " !'@&Q9#-LS:4](  ":"@( '@
M@ $     8W5T;&5R+6AQ>6-E;V5M<&QO>6UE;G1A9W(N:'1M4$L! A0#%
M  @ 1X!L6::*IZ201P  L@," !X              ( !BT@  &-U=&QE<BUH
M<7EI;F1E;6YI9FEC871I;VYA+FAT;5!+ 0(4 Q0    ( $> ;%E1I^WXP18
M .^"   -              "  5>0  !E<W M='-A=F8N:'1M4$L! A0#%
M  @ 1X!L6=ZKGD^U$   TD4  !(              ( !0Z<  &=O;&1E;F=A
M=&5P<G9F+FAT;5!+ 0(4 Q0    ( $> ;%G:SUK(D1X  $NI   0
M      "  2BX  !H<7DM,C R-#$Q,3$N:'1M4$L! A0#%     @ 1X!L631[
M,QEH @   P<  !               ( !Y]8  &AQ>2TR,#(T,3$Q,2YX<V10
M2P$"% ,4    " !'@&Q9]&3"9'X*   /60  %               @ %]V0
M:'%Y+3(P,C0Q,3$Q7VQA8BYX;6Q02P$"% ,4    " !'@&Q9N<F^A=@&   #
M,P  %               @ $MY   :'%Y+3(P,C0Q,3$Q7W!R92YX;6Q02P4&
2      @ "  3 @  -^L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>hqy-20241111_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hqy-20241111.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001428336</identifier>
        </entity>
        <period>
            <startDate>2024-11-11</startDate>
            <endDate>2024-11-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001428336</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">HEALTHEQUITY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36568</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">52-2383166</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">15 West Scenic Pointe Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Draper</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">84020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">727-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">HQY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
